CD1d- and MR1-Restricted T Cells in Sepsis by Peter A. Szabo et al.
August 2015 | Volume 6 | Article 4011
Review
published: 12 August 2015
doi: 10.3389/fimmu.2015.00401
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Nilabh Shastri, 
University of California Berkeley, USA
Reviewed by: 
Olivier Lantz, 
Institut Curie, France 
Weiming Yuan, 
University of Southern California, USA
*Correspondence:
 S. M. Mansour Haeryfar, 
Department of Microbiology and 
Immunology, Schulich School of 
Medicine and Dentistry, Western 
University, 1151 Richmond Street, 
London, ON N6A 5C1, Canada 
mansour.haeryfar@schulich.uwo.ca
†Peter A. Szabo and Ram V. Anantha 
have contributed equally to this work.
Specialty section: 
This article was submitted to T Cell 
Biology, a section of the journal 
Frontiers in Immunology
Received: 05 June 2015
Accepted: 22 July 2015
Published: 12 August 2015
Citation: 
Szabo PA, Anantha RV, Shaler CR, 
McCormick JK and Haeryfar SMM 
(2015) CD1d- and MR1-restricted 
T cells in sepsis. 
Front. Immunol. 6:401. 
doi: 10.3389/fimmu.2015.00401
CD1d- and MR1-restricted T cells in 
sepsis
Peter A. Szabo 1†, Ram V. Anantha 1,2†, Christopher R. Shaler 1, John K. McCormick 1,3,4 and 
S.M. Mansour Haeryfar 1,3,4,5*
1 Department of Microbiology and Immunology, Western University, London, ON, Canada, 2 Division of General Surgery, 
Department of Medicine, Western University, London, ON, Canada, 3 Centre for Human Immunology, Western University, 
London, ON, Canada, 4 Lawson Health Research Institute, London, ON, Canada, 5 Division of Clinical Immunology and 
Allergy, Department of Medicine, Western University, London, ON, Canada
Dysregulated immune responses to infection, such as those encountered in sepsis, can 
be catastrophic. Sepsis is typically triggered by an overwhelming systemic response to 
an infectious agent(s) and is associated with high morbidity and mortality even under 
optimal critical care. Recent studies have implicated unconventional, innate-like T lym-
phocytes, including CD1d- and MR1-restricted T cells as effectors and/or regulators of 
inflammatory responses during sepsis. These cell types are typified by invariant natural 
killer T (iNKT) cells, variant NKT (vNKT) cells, and mucosa-associated invariant T (MAIT) 
cells. iNKT and vNKT cells are CD1d-restricted, lipid-reactive cells with remarkable 
immunoregulatory properties. MAIT cells participate in antimicrobial defense, and are 
restricted by major histocompatibility complex-related protein 1 (MR1), which displays 
microbe-derived vitamin B metabolites. Importantly, NKT and MAIT cells are rapid and 
potent producers of immunomodulatory cytokines. Therefore, they may be considered 
attractive targets during the early hyperinflammatory phase of sepsis when immediate 
interventions are urgently needed, and also in later phases when adjuvant immuno-
therapies could potentially reverse the dangerous state of immunosuppression. We will 
highlight recent findings that point to the significance or the therapeutic potentials of NKT 
and MAIT cells in sepsis and will also discuss what lies ahead in research in this area.
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Preamble
Sepsis is a life-threatening syndrome typically associated with early hyperinflammation, immuno-
suppression in its protracted phase, and a continuum of organ dysfunction abnormalities. It is a 
significant cause of death across all age groups and in both developed and developing countries. It 
also negatively affects the quality of life among survivors. Sepsis is usually a consequence of infection 
although sterile tissue damage inflicted by non-infectious causes or conditions, such as pancreatitis, 
ischemia–reperfusion injury, and cancer may also lead to sepsis (1). In this article, we will only 
focus on the syndrome caused by disproportionate, excessive, or sometimes defective host responses 
to infection. We will provide a general overview of sepsis, its epidemiology, prognosis, manage-
ment, and immunopathogenesis. We will briefly discuss experimental immunotherapeutic strate-
gies tested in animal models of sepsis or used in clinical trials. Many such strategies have targeted 
antigen-presenting cells (APCs) and conventional T cells or their products, such as inflammatory 
cytokines, albeit with little success. Recent progress in our understanding of natural killer T (NKT) 
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cell and mucosa-associated invariant T (MAIT) cell responses to 
infection and their regulatory functions may open a new front 
in our fight against sepsis. These unconventional T cells respond 
rapidly to infection by secreting large quantities of pro- and/or 
anti-inflammatory cytokines, thereby controlling the effector 
functions of numerous other cell types belonging to both innate 
and adaptive arms of immunity. Also importantly, NKT cells can 
be easily manipulated by “disease-tailored” synthetic glycolipids. 
Therefore, the quick and wide-ranging actions of NKT cells, and 
potentially of MAIT cells, may be exploited to the host’s benefit 
in different forms or stages of sepsis. We will review NKT and 
MAIT cell functions in antimicrobial immunity and highlight 
recent findings on these cell types in the context of sepsis.
NKT Cells: A Brief Overview
Natural killer T cells are innate-like T lymphocytes with impressive 
immunomodulatory properties. They express glycolipid-reactive 
αβ T cell receptors (TCRs) along with several characteristic 
markers of NK cells (e.g., mouse NK1.1 and human CD161) (2, 
3). NKT cells develop in the thymus where they are positively 
selected by CD1d+CD4+CD8+ thymocytes and consequently 
become “CD1d-restricted” (4). As such, CD1d-deficient mice 
are devoid of NKT cells (5). CD1d is a monomorphic major 
histocompatibility complex (MHC) class I-like glycoprotein that 
is highly conserved across mammalian species (6). It is a member 
of the CD1 family of lipid antigen (Ag)-presenting molecules (7, 
8). The CD1 family in human has five members, namely CD1a–e, 
while rodents only express CD1d. Murine and human CD1d can 
present normal self- and tumor-derived lipids as well as microbial 
glycolipids to NKT cells. The discovery of CD1d restriction led 
to the invention of glycolipid-loaded CD1d tetramer reagents 
enabling accurate tracking, enumeration, and phenotypic and 
functional analysis of NKT cells (9–11).
The major subset of NKT cells is defined by the expression 
of a canonical or invariant TCR (iTCR) with a unique α chain 
rearrangement (Vα14–Jα18 and Vα24–Jα18 in mice and humans, 
respectively), which is paired with one of only a limited choices of 
β chains (Vβ8.2, Vβ2 or Vβ7 in mice and Vβ11 in humans). These 
cells are called type I or invariant NKT (iNKT) cells (2, 3). Two 
phenotypically distinct subpopulations of iNKT cells have been 
identified in mice, the CD4+CD8− subset and the double-negative 
(CD4−CD8−) subset (12). An additional CD8α+ subset exists in 
humans (13). iNKT cells constitutively express CD69, CD25, and 
CD44 on their surface, which is consistent with their “partially-
activated” or “memory-like” status even in germ-free mice (14) 
and in human cord blood (15).
iNKT cells are present at low frequencies in the circulation 
and in various tissues including bone marrow, thymus, spleen, 
and lymph nodes. However, they are abundant in the mouse 
liver and in the human omentum (16). The prevalence of iNKT 
cells varies considerably among different individuals for reasons 
that are currently unknown. Also importantly, iNKT cell subsets 
found in different anatomical locations exhibit functional or 
even transcriptional heterogeneity. For instance, interleukin 
(IL)-4- and IL-13-producing human peripheral blood iNKT cells 
fall exclusively within the CD4+ subset, whereas iNKT cells that 
synthesize tumor necrosis factor (TNF)-α and interferon (IFN)-γ 
upon ex vivo stimulation can be either CD4+ or double negative 
(17). Another example is the case of adipose tissue iNKT cells that 
secrete IL-10, impart an anti-inflammatory phenotype to mac-
rophages, and control the expansion and suppressor function of 
regulatory T (Treg) cells (18). Moreover, adipose tissue iNKT cells 
lack promyelocytic leukemia zinc finger (PLZF), a transcription 
factor otherwise regarded as a “master regulator” of iNKT cell 
effector functions (19).
iNKT cells are armed with cytotoxic effector molecules such 
as perforin, granzymes, TNF-α, Fas ligand, and TNF-related 
apoptosis-inducing ligand (TRAIL), and may be able to lyse 
neoplastic or infected cells directly (20–22). However, they are 
best known for their immunomodulatory functions mediated 
by the early production of pro- and/or anti-inflammatory 
cytokines. iNKT cells can thus transactivate numerous down-
stream effector cell types including natural killer (NK) cells, 
macrophages, dendritic cells (DCs), conventional CD4+ 
and CD8+ T cells, and B cells. They are rapid producers of 
enormous quantities of T helper (Th)1-, Th2-, and Th17-type 
cytokines, although Th9- and Th10-like iNKT cells have also 
been described (23, 24). The constitutive presence of pre-
formed messenger RNA (mRNA) encoding at least some of 
such cytokines in iNKT cells explains the rapidity with which 
they are released (25).
The identity of endogenous CD1d ligand(s) that participate in 
positive selection and also perhaps in peripheral maintenance of 
iNKT cells remains ill-defined and controversial. iNKT cells can 
recognize and respond to certain glycolipids present in various 
microbes, including but not limited to Novosphingobium spp., 
Ehrlichia spp., Borrelia burgdorferi, Streptococcus pneumoniae, 
and Streptococcus agalactiae (26–28). Of note, the latter pathogen, 
which is often referred to as group B streptococcus, is a common 
cause of neonatal sepsis.
Of all exogenous glycolipid agonists of iNKT cells, 
α-galactosylceramide (α-GalCer) has been used most extensively, 
not only as a research tool but also in clinical trials for cancer 
and viral diseases (29). α-GalCer was initially isolated from an 
extract of a marine sponge called Agelas mauritanius (30), and 
is believed to have originated from microbes co-existing in a 
symbiotic relationship with this sponge. Until recently, α-GalCer 
was considered to be a merely exogenous and unnatural glycolipid 
given the presence of only one glucosylceramide synthase and one 
galactosylceramide synthase in mammalian species, both of which 
are β-transferases. However, a recent report has demonstrated 
the presence of endogenous α-anomeric glycolipids includ-
ing α-GalCer in mammals, due perhaps to the operation of an 
“unfaithful” enzyme or a novel, as-yet-unidentified pathway (31).
α-GalCer and its analogs possess a lipid tail that can be 
buried deep inside the hydrophobic pocket of CD1d, while 
their galactose head protrudes out of CD1d to be contacted by 
the iTCRα chain (32). The length and composition of acyl and 
phytosphingosine chains of synthetic α-GalCer analogs impact 
the binding affinity of α-GalCer:CD1d:iTCR interactions 
(33), which partially determines the type of cytokines that an 
activated iNKT cell will secrete. For example, OCH is a sphin-
gosine-truncated derivative of α-GalCer with Th2-skewing 
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characteristics (34). We have successfully used this glycolipid 
to delay Th1-mediated cardiac allograft rejection (35), to pre-
vent or cure citrulline-induced autoimmune arthritis (36), and 
to reduce the severity of intra-abdominal, polymicrobial sepsis 
(37) in mouse models. Another Th2-favoring agonist of iNKT 
cells is C20:2, an α-GalCer analog with a short fatty acyl chain 
containing two unsaturation sites at carbon-11 and -14 posi-
tions (38). C20:2 is reportedly superior to OCH in polarizing 
human iNKT cells. Th1-biasing ligands of iNKT cells can be 
exemplified by a C-glycoside analog of α-GalCer, also known 
as α-C-GalCer, which potentiates IL-12 and IFN-γ production 
in mice (39). Therefore, α-C-GalCer may be useful in adjuvant 
glycolipid immunotherapy of cancer and infectious diseases.
Cell membrane location of glycolipid loading onto CD1d 
and its presentation within or outside lipid rafts (40), the type 
of CD1d+ APCs involved (41), the presence and intensity of 
costimulatory and danger signals transmitted or exchanged (29), 
and the cytokine milieu in which iNKT cell priming occurs are 
among other important factors that shape the cytokine profiles of 
iNKT cells. Remarkably, mouse iNKT cells can recognize human 
CD1d and vice versa (6), and iNKT cells from either species are 
responsive to α-GalCer. Therefore, at least some of the findings 
obtained in mouse models of CD1d-mediated iNKT cell activa-
tion are likely to be translatable to the clinic.
iNKT cells can also be activated in the absence of exog-
enous glycolipids. During infection, microbial components 
may engage pattern recognition receptors (PRRs), such as 
Toll-like receptors (TLRs) on APCs, thus resulting in secretion 
of IL-12 and IL-18. Together, these cytokines trigger indirect 
activation of iNKT cells (42, 43), which is often dependent 
upon the presence of CD1d. This indicates an intriguing but 
poorly understood role for endogenous lipids in the context 
of antimicrobial immunity. A combination of IL-12 and IL-18 
can also reportedly induce iNKT cell responses in a truly iTCR-
independent fashion (44). We recently reported that group II 
bacterial superantigens (SAgs) can directly activate iNKT 
cells in a CD1d-independent manner (45). Therefore, iNKT 
cells may serve as effectors and/or regulators of early cytokine 
responses to bacterial SAgs.
Type II or variant NKT (vNKT) cells are CD1d-restricted 
cells with a relatively diverse αβ TCR repertoire (3, 11). They 
exhibit reactivity with certain self lipids, but not with α-GalCer 
(46). Compared with iNKT cells, vNKT cells are less frequent 
in mice but more prevalent in humans (47). A major fraction 
of vNKT cells can recognize sulfatide, a self glycolipid that is 
highly enriched in the central nervous system, kidney and liver 
(48). Several other endogenous lipids, including but not limited 
to β-d-glucopyranosylceramide (β-GlcCer), have also been 
recently discovered to activate vNKT cells (49). Given the relative 
promiscuity of vNKT cell Ag receptors, it is not too far-fetched to 
envisage scenarios where vNKT cells recognize microbial lipids 
cross-reactive to self components. In addition, infection may lead 
to the release of self lipids in sufficient quantities to induce vNKT 
cell activation.
Our overall understanding of vNKT cell responses in health 
and disease is limited. This is in large part due to a lack of firm 
molecular markers, stable reagents and direct methods to detect 
and characterize vNKT cells. Sulfatide-loaded CD1d-tetramer 
reagents have been generated (46). However, they are not popu-
lar due to their low stability and high background staining. In 
addition, there is no mouse model of pure vNKT cell deficiency. 
CD1d−/− mice are devoid of both iNKT and vNKT cells since 
CD1d is required for the positive selection of both cell types in 
the thymus (50). Experimental evidence indicates that vNKT cells 
have an activated phenotype and depend on PLZF for their devel-
opment (49), and that vNKT and iNKT cells may exert opposing 
functions with broad implications for antitumor responses (51) 
and antimicrobial immunity (52, 53).
MAiT Cells and Their Roles in Microbial 
immunity
MAIT cells are another evolutionarily conserved subset of 
innate T lymphocytes that have captured the attention of the 
immunological community in the past few years (54, 55). MAIT 
cells develop in the thymus where they rearrange their semi-
invariant TCR with a characteristic Vα19–Jα33 and Vα7.2–Jα33 
TCRα chain in mice and humans, respectively (56, 57).
Similar to NKT cells, MAIT cells are positively selected by 
CD4+CD8+ thymocytes (58). However, their selection requires 
the expression of MHC-related protein 1 (MR1), as opposed to 
CD1d, on thymocytes. Accordingly, MR1-deficient mice lack 
MAIT cells in their T cell repertoire (59). MR1 is a monomorphic, 
non-classical MHC I molecule that is markedly conserved among 
various mammals (60–62). There is 90% sequence homology 
between mouse and human MR1 ligand-binding domains and a 
high degree of functional cross-reactivity, which is highly remi-
niscent of cross-species CD1d conservation.
MAIT cells are infrequent and immature in the human fetal 
thymus (63). Their maturation is accompanied by a gradual, post-
thymic acquisition of PLZF expression and the ability to secrete 
IFN-γ and IL-22 upon exposure to microbes in mucosal layers. 
A PLZF-expressing CD161highCD8+ population is detectable in 
human cord blood, from which Vα7.2+ MAIT cells emerge in 
adults (64).
MAIT cells are severely depleted in B cell-deficient patients 
and mice, and are also entirely absent in the peripheral tissues 
of germ-free mice (59), indicating that B cells and commensal 
microflora are essential for MAIT cell peripheral maintenance/
expansion. Therefore, it is not surprising that MAIT cells prefer-
entially accumulate in the mucosal compartments, such as the gut 
lamina propria, hence their denomination. MAIT cells are also 
present in other tissues. In human, they are particularly abundant 
in peripheral blood and can comprise up to ~50% of all T cells 
in the liver (65, 66). There are far fewer MAIT cells in mice than 
in humans. This, together with other differences between the 
two species (67), indicates that caution needs to be exercised in 
extrapolating experimental data from mice to human conditions.
Until recently, there was no single reagent to directly detect 
mouse MAIT cells. In addition, human MAIT cells have been 
commonly defined as CD3+Vα7.2+CD161+. However, recent 
identification of a MAIT cell Ag, namely reduced 6-hydroxym-
ethyl-8-d-ribityllumazine (rRL-6-CH2OH), led to the develop-
ment of MR1 tetramer reagents loaded with this compound to 
August 2015 | Volume 6 | Article 4014
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
accurately identify mouse and human MAIT cells (68). Once 
widely available, these reagents will undoubtedly boost research 
in the area of MAIT cell biology. Human peripheral blood MAIT 
cells are CD45RA−CD45RO+CD62LlowCD95high, which is consist-
ent with an effector memory phenotype (65). They also express 
the receptors for IL-12, -18, and -23. Human hepatic MAIT cells 
have a more activated phenotype and express elevated levels of 
CD69 in comparison with their blood counterparts (66). They are 
also human leukocyte Ag (HLA)-DR+ and CD38+. This may be 
due to continuous exposure to microbial Ags accessing the liver 
from the gut through the portal system.
MAIT cells bridge innate and adaptive arms of immunity 
to microbial intruders. They quickly amass in sites of infection 
where they can keep pathogens in check. For instance, in a mouse 
model of pulmonary infection with Francisella tularensis, MAIT 
cells reduce bacterial burden in the lungs and prevent mortality 
from infection even in the absence of conventional T cells (69). 
They can produce inflammatory cytokines such as IFN-γ, IL-17, 
and TNF-α readily, amply and promptly after TCR stimulation 
(54, 55). Human MAIT cells express granzymes A and K, and 
are able to kill infected cells (70). They were shown to lyse, in an 
MR1-dependent fashion, epithelial cells infected by the intestinal 
pathogen Shigella flexneri (71), and THP1 monocytic cells infected 
by Escherichia coli (E. coli) (70). MAIT cells are responsive to a 
variety of bacteria and yeasts including Lactobacillus acidophilus, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus 
aureus (S. aureus), Staphylococcus epidermidis, Candida albicans, 
Candida galbrata, and Saccharomyces cerevisiae. A limited 
number of studies have utilized MR1-deficient mice to explore 
the antimicrobial potentials of MAIT cells in  vivo. The ability 
to control infection with Klebsiella pneumoniae, Mycobacterium 
bovis bacillus Calmette–Guérin (BCG), or Francisella tularensis 
was found to be impaired in MR1-deficient mice (69, 72, 73).
McCluskey’s and Rossjohn’s research teams discovered that 
vitamin B metabolites represent a class of MR1-restricted Ags 
(74). A folic acid (vitamin B9) metabolite called 6-formyl pterin 
(6-FP) was found to bind MR1 without stimulating MAIT cells. 
In contrast, MR1 ligands derived from the riboflavin (vitamin 
B2) biosynthesis pathway could activate MAIT cells. Of note, this 
pathway is operational in all of the microorganisms that activate 
MAIT cells, but not in those that reportedly fail to do so.
To confirm that the riboflavin pathway supplies human MAIT 
cell ligands, Corbett et al. mutated various enzymes of the ribofla-
vin operon in the Gram-positive bacterium Lactococcus lactis fol-
lowed by testing the MAIT cell-activating capacity of the mutants 
(75). This approach led to the identification of 5-amino-6-d-ribi-
tylaminouracil (5-A-RU), an early intermediate of the riboflavin 
pathway, as a key compound in generating MAIT cell “neo-
antigens.” Through non-enzymatic interactions, 5-A-RU forms 
simple adducts with small molecules arising from other metabolic 
pathways (e.g., glycolysis), such as glyoxal and methylglyoxal, thus 
giving rise to 5-(2-oxoethylideneamino)-6-d-ribytilaminouracil 
(5-OE-RU) and 5-(2-oxopropylideneamino)-6-d-ribytilaminou-
racil (5-OP-RU), respectively. MR1 in turn captures, stabilizes, 
and presents these neo-antigens to MAIT cells. Recent work 
from Olivier Lantz’s laboratory demonstrated that most, if not 
all, mouse MAIT cell ligands harbored by the Gram-negative 
bacterium E. coli are also related to the riboflavin pathway (76). 
MR1-mediated activation of mouse MAIT cells was most robust 
upon stimulation with a mixture of 5-A-RU and methylglyoxal, 
and also detectable when a combination of 5-A-RU and glyoxal 
was used. This study also reported the synthesis of a new 6-FP 
variant in which the amine and the formyl group are blocked. 
This compound could efficiently inhibit the activation of MAIT 
cells by semipurified soluble bacteria (SPB) or by 5-A-RU plus 
methylglyoxal, and may therefore represent a new class of inhibi-
tors of MAIT cell activation. Finally and importantly, in  vivo 
activation of MAIT cells was demonstrated for the first time when 
iVα19 transgenic mice on a Cα−/− background, which harbor 
many MAIT cells, were directly injected with the SPB fraction 
from riboflavin-sufficient E. coli or with a mixture of 5-A-RU and 
methylglyoxal. Interestingly, administration of 5-A-RU alone 
failed to activate MAIT cells, which may be probably due to its 
instability and/or low bioavailability for interaction with small 
metabolites and loading onto MR1 (76).
Mammals do not synthesize riboflavin, but host-derived 
metabolites could potentially generate adducts with 5-A-RU of 
bacterial origin (75). MR1-restricted recognition of the formed 
neo-antigens may be considered a new mechanism of self–non-
self discrimination, especially in mucosa-associated lymphoid 
tissues. MR1 ligands are ubiquitous and present in many bacteria, 
including commensals. In addition, they can readily diffuse across 
epithelial barriers (55). Therefore, how MAIT cell activation is 
controlled in vivo remains enigmatic at this point.
MR1-independent responses can also be mounted by MAIT 
cells. The in vitro response of MAIT cells to BCG-infected cells is 
an example (73). Moreover, MAIT cells can produce IFN-γ when 
cultured with a combination of IL-12 and IL-18 in the absence 
of TCR triggering (77). Therefore, bystander activation of MAIT 
cells may occur during infection with viral pathogens or other 
germs that do not harbor MR1 ligands.
Sepsis
Definitions and epidemiology
Although sepsis is often discussed in the context of intensive 
care in modern settings, the syndrome is almost as old as medi-
cine itself. Derived from the Greek sipsi meaning “make rotten,” 
the term sepsis was first coined by Hippocrates (460–370 BC) to 
describe the unpleasant process of organic matter putrefaction 
(78). Avicenna (980–1037 AD), the great Persian physician/
scientist/philosopher, noted the frequent coincidence of blood 
putrefaction, what is known today as septicemia, and fever in 
the aftermath of surgery (79). The centuries that followed wit-
nessed important discoveries linking germs to a wide array of 
disorders including sepsis. However, the germ theory of disease 
failed to fully explain the pathogenesis of sepsis since many 
patients succumbed to it despite successful eradication of the 
microbial intruder(s). Therefore, the host response to the germ, 
and not the germ per se, was proposed to drive the pathogenesis 
of sepsis (80).
The modern terminology for sepsis and its sequelae was stand-
ardized during an American College of Chest Physicians/Society 
of Critical Care Medicine Consensus Conference in 1991 (81). 
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Accordingly, sepsis is defined as documented or suspected infec-
tion accompanied by at least two of the following abnormalities: 
(i) a body temperature of >38°C or <36°C; (ii) a heart rate of >90 
beats/min; (iii) a respiratory rate of >20 breaths/min or PaCO2 
of <32  mm Hg; (iv) a blood leukocyte count of >12,000/mm3 
or <4,000/mm3, or detection of >10% immature neutrophils 
(aka. band cells) in the leukocyte differential count. The panel of 
experts recommended the application of the term “severe sepsis” 
when sepsis is further complicated by organ dysfunction, perfu-
sion abnormalities (e.g., lactic acidosis, oliguria, acute alteration 
in mental status), or hypotension (a systolic blood pressure of 
<90 mm Hg or a reduction of ≥40 mm Hg from the baseline in 
the absence of other causes of hypotension). It needs to be noted 
that the terms “sepsis” and “severe sepsis” have often been used 
interchangeably. Finally, a severely septic patient should be clas-
sified as having “septic shock” when her/his hypotensive state is 
refractory to fluid resuscitation.
Sepsis is a leading cause of death following hospitalization and 
represents a major challenge in the management of critically ill 
patients in non-coronary intensive care units (ICUs) (82). It is 
estimated that 25% of patients who develop severe sepsis die dur-
ing hospitalization, and septic shock is associated with mortality 
rates approaching 50% (83). Alarmingly, the incidence of severe 
sepsis is on the rise (84). Of equal importance, sepsis worsens the 
quality of life among survivors and increases their risk of morbid-
ity and early death. In fact, the 5-year mortality rate in the sepsis 
survivor pool can be as high as 75% (84).
Risk Factors and Prognosis
In general, the prognosis of sepsis is dependent upon demo-
graphic, socioeconomic, and iatrogenic factors in addition to 
the patient’s medical history, immunological, nutritional and 
overall health status, and the type of microorganism(s) involved 
in triggering or perpetuation of sepsis (79, 85). For instance, 
being over 65 years of age, being a male, being a nursing home 
resident, being in a poor nutritional state, having low house-
hold income, or receiving treatment in a non-teaching hospital 
predisposes to sepsis and to its elevated severity. Several studies 
have found that age is an independent predictor of mortality 
from sepsis (86–88). However, the elderly are vulnerable to sepsis 
also due to a higher likelihood of pre- or co-existing morbidities 
(e.g., diabetes and cardiovascular problems) requiring medica-
tion, malnutrition, repeated and/or prolonged hospitalizations, 
decline in immunity, and functional restrictions (89). Some 
of the above factors are taken into account in calculation of 
Mortality in Emergency Department Sepsis (MEDS) score to 
predict 1-year mortality (85).
Adverse iatrogenic factors include steroid therapy and 
immunosuppression prior to surgery and a need for multiple 
operations (79). Invasive devices such as urinary and intra-
venous catheters and breathing tubes also increase the risk of 
sepsis. The main predisposing factor for urinary tract infections, 
which are the most frequent nosocomial infections in surgical 
patients, is the usage of an indwelling urinary catheter. Vascular 
catheters, especially central venous catheters, are also common 
vehicles for nosocomial infections caused by Gram-positive skin 
commensals.
It cannot be overstated that the prognosis of sepsis is also 
determined by the speed with which the diagnosis is established 
and proper management strategies implemented. The earlier the 
treatment is started, the more favorable the outcome will be.
Clinical Management
Despite advances in our understanding of sepsis at organismal, 
cellular and molecular levels, not even a single drug is approved 
as a mechanism-based treatment option for sepsis. The clinical 
guidelines established by the Surviving Sepsis Campaign (SSC), 
an international consortium of professional societies commit-
ted to reducing mortality from severe sepsis and septic shock, 
are organized into two “bundles,” each comprising a select but 
non-specific set of care elements distilled from evidence-based 
practice (90). The initial “resuscitation bundle” should be applied 
within 6 h after the patient’s presentation to prevent or resolve 
cardiorespiratory insufficiency and to combat the immediate 
threats posed by uncontrolled infection(s). Hemodynamic resus-
citation is achieved by administration of intravenous fluids and 
vasopressors while oxygen therapy and mechanical ventilation 
can also be supplied as needed. The timely management of infec-
tion requires obtaining blood cultures before broad-spectrum 
antibiotic therapy is launched as well as source control (e.g., drain-
age of pus). The subsequent “management bundle” is typically 
accomplished in the ICU where the attention is shifted toward 
monitoring and supporting vital organ functions and avoiding 
complications. In addition, the efficacy of antibiotic therapy is 
evaluated for potential de-escalation to prevent the emergence of 
microbial resistance and to lower the risk of drug toxicity (90, 91).
A recent meta-analysis of 13 randomized controlled trials has 
demonstrated that early goal-directed therapy, which is perhaps 
best exemplified by the SSC-recommended resuscitation bundle, 
reduces overall mortality from sepsis when initiated within the 
first 6 h (92). This should reinforce the notion that there usually 
exists a short window of opportunity in which current manage-
ment strategies or novel future therapies are expected to be most 
effective.
immunopathogenesis and immunosuppression 
in Sepsis
Disproportionate or dysregulated immune responses to infection 
constitute a major culprit in sepsis-related death. Sepsis is no 
longer considered a merely or even mainly hyperinflammatory 
syndrome. Rather, in “sepsis-prone” individuals and conditions, 
infection triggers a highly complex response that is variable in 
proportion or in pro- versus anti-inflammatory nature depend-
ing upon the pathogen load and virulence, genetic and other 
host factors including age and co-morbidities, and the time 
point at which the response is evaluated (91). Pro-inflammatory 
responses mounted in septic patients help eradicate the inciting 
microbe(s) but may cause collateral organ damage. On the other 
hand, anti-inflammatory and immunosuppressive mechanisms 
contribute to tissue recovery but also make the patient susceptible 
to secondary infections and opportunistic pathogens, especially 
during protracted sepsis (93).
The pioneering studies of Tracey et al. in the mid-1980s revealed 
that many deleterious features of endotoxin administration to 
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rats could be simulated by human cachectin (aka. TNF) (94) and 
that cachectin-neutralizing antibody F(ab′)2 fragments could 
prevent acute and otherwise lethal septic shock in E. coli-infected 
baboons (95). We now know that acute septic shock, which occurs 
in a relatively small fraction of patients with sepsis, is indeed a 
dangerous immunopathology mediated by an overly exuber-
ant TNF response (91). TNF-α and other pro-inflammatory 
cytokines including IL-1β and IL-6 and chemokines like IL-8 are 
released from activated macrophages and other APCs after they 
sense the presence of invading microbes by PRRs (e.g., TLRs) and 
phagocytose them. This in turn leads to neutrophil mobilization, 
lymphocyte activation, and more pro-inflammatory cytokine 
(e.g., IFN-γ) secretion. These cytokines limit microbial infections, 
but their elevated levels are associated with a poor outcome in 
sepsis (96, 97). The pleotropic cytokine IL-3 was recently found to 
be an upstream orchestrator of inflammation in the early phase of 
polymicrobial sepsis modeled by the cecal ligation and puncture 
(CLP) procedure in mice (98). In addition, retrospective and 
prospective analyses of plasma IL-3 in septic patients linked 
heightened levels of this cytokine to a poor outcome.
Both pro- and anti-inflammatory processes get underway 
promptly after the initiation of sepsis. A hyperinflammatory 
“cytokine storm” dominates the initial phase in many patients 
and accounts for death within the first 3 days from septic shock 
and multiple organ failure in a substantial fraction of patients 
(99). However, more than 70% of deaths due to sepsis occur after 
the first 3 days, with many occurring weeks later. One needs to 
keep in mind that many, if not most, epidemiological studies on 
sepsis have been conducted in developed countries with an aging 
population and advanced ICU facilities. Therefore, the reported 
decline in mortality rates of early sepsis is likely owed to better 
management protocols and also perhaps a reflection of immu-
nosenescence in the elderly.
Death during protracted sepsis is sometimes the result of the 
family’s decision to withdraw aggressive support measures to 
switch to palliative care for patients with severe co-morbidities 
and a slim chance of recovery. However, the fact remains that 
with or without such decisions, many patients in this phase 
succumb to stubborn infections that are difficult to resolve even 
with broad-spectrum antimicrobial therapy and infection source 
control (100). In a retrospective review of macroscopic autopsy 
findings, approximately 77% of surgical ICU patients who had 
died from sepsis or septic shock were found to have continuous 
septic foci (101), suggesting a failure to clear the inciting patho-
gen and/or to eradicate nosocomial infections. This is thought 
to be a consequence of immunosuppression (99, 100), especially 
in patients who survive the early hyperinflammatory phase. 
The reported inability of many septic patients to elicit normal 
delayed-type hypersensitivity (DTH) skin reactions to standard 
recall Ags (102) and the frequent reactivation of latent viruses 
(e.g., cytomegalovirus, Epstein–Barr virus, herpes simplex virus, 
human herpesvirus-6), sometimes involving multiple viruses at 
the same time in prolonged sepsis (103), also point to a profound 
state of immunosuppression.
Multiple other findings lend support to the notion of sepsis-
induced immunosuppression. In an earlier study, van Dissel et al. 
demonstrated that a high ratio of plasma IL-10:TNF-α correlates 
with increased mortality in febrile patients with community-
acquired infection and cautioned against the application of pro-
inflammatory cytokine inhibition in sepsis (104). In a separate 
study, circulatory levels of IL-10 paralleled the sepsis score, and 
its sustained overproduction was deemed a predictor of severity 
and fatal outcome (105).
A global cytokine depression has been noted in numer-
ous other studies. After stimulation with lipopolysaccharide 
(LPS), whole blood samples from septic patients contained 
less IL-1β, TNF-α, and IL-6 in comparison with samples 
obtained from non-septic patients admitted for hernia repair 
or cholecystectomy (106). Munoz et  al. reported a profound 
decrease in the ability of freshly isolated monocytes from ICU 
patients with sepsis to produce IL-1β, TNF-α, and IL-6 fol-
lowing ex vivo exposure to LPS (107). An important finding 
of this investigation was that monocytes from the survivor 
subpopulation, but not from those who eventually died from 
sepsis, regained their cytokine production capacity. Also inter-
estingly, the blunted pro-inflammatory cytokine response was 
most pronounced in patients with Gram-negative infections. 
This may be a manifestation of the long-known phenomenon 
of “endotoxin tolerance,” according to which LPS-exposed 
cells become refractory to subsequent LPS challenges (108). 
Endotoxin tolerance arguably serves to protect against uncon-
trolled inflammation in sepsis, but is also correlated with a 
high risk of secondary infection and mortality. In septic 
patients, monocytes are also hyporesponsive to CD40 ligation, 
which would otherwise result in the upregulation of classic 
costimulatory molecules B7-1 (CD80) and B7-2 (CD86) and 
enhanced ability of monocytes to activate T lymphocytes 
(109). The CD40–CD40L cross-talk does not directly involve 
the CD14/TLR-4 pathway governing cellular responses to LPS. 
Therefore, endotoxin tolerance may only partially explain 
monocyte hyporesponsiveness in sepsis.
Sepsis-induced immunological shortcomings are not limited 
to leukocytes traveling in the bloodstream. Boomer et al. found 
that post-mortem splenocytes from septic patients secreted 
significantly less TNF-α, IFN-γ, IL-6, and IL-10 in response 
to LPS, CD3/CD28 co-ligation, or stimulation with phorbol 
12-myristate 13-acetate (PMA) plus ionomycin when compared 
with splenocytes from patients who were declared brain dead or 
those who underwent emergency splenectomy due to trauma 
(110). Moreover, cytofluorimetric analyses of splenic cell popula-
tions revealed signs of T cell exhaustion or anergy. For instance, 
the frequency of CD4+ T cells displaying the anergy/exhaustion 
marker programmed cell death 1 (PD-1) and that of CD8+ T 
cells expressing the prototype co-inhibitory molecule cytotoxic 
T-lymphocyte antigen-4 (CTLA-4) were higher in septic than in 
control patients. Both subsets also expressed low levels of IL-7 
receptor α chain (CD127) that promotes cell survival. Consistent 
with these observations, splenic APCs from septic patients exhib-
ited decreased B7-2 and HLA-DR and increased PD-ligand 1 
(PD-L1) levels. It is noteworthy that weak expression of HLA-DR 
is a common abnormality in sepsis. In fact, measuring monocytic 
HLA-DR levels has been used to identify an immunosuppressed 
state in patients with sepsis and septic shock and to monitor the 
efficacy of sepsis immunotherapy (111).
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Boomer et al. also demonstrated that within the post-mortem 
lung tissues of septic patients, PD-1 expression on CD4+ cells and 
PD-L1 expression on plasmacytoid dendritic cells (pDCs) were 
augmented in comparison with control lung tissues obtained 
from transplant donors or cancer resections (110). Finally, this 
comprehensive study reported two- and three-fold increases in 
the frequencies of splenic Treg cells and lung myeloid-derived 
suppressor cells (MDSCs), respectively, in sepsis. Treg cells are 
relatively resistant to sepsis-induced apoptosis, and their per-
centage increases also in the circulation of patients with sepsis 
(99, 112). Using the CLP mouse model, Delano et  al. found 
that GR-1+CD11b+ MDSCs that produce IL-10 among other 
cytokines and skew T cell responses toward a Th2 phenotype 
increase numerically and remain elevated within the spleen, 
lymph nodes, and bone marrow (113). Therefore, suppressor cell 
function appears to be a significant component of immunosup-
pression in sepsis.
Apoptotic death of naïve and adaptive cells of the immune 
system also contributes to immunosuppression. We detected 
widespread apoptosis in the spleen of mice with feces-induced 
peritonitis (FIP), which we used as a model of intra-abdominal 
sepsis (114). This was due to a profound apoptotic loss of splenic 
T cells, B cells, NK cells, and macrophages (37). Hotchkiss et al. 
performed rapid tissue harvesting at the bedside of patients dying 
from sepsis and demonstrated a marked loss of splenic CD4+ T 
cells, B cells and DCs (115, 116). Felmet and coworkers reported 
similar depletions, prolonged lymphopenia, and hypocellularity 
accompanied by apoptosis in the thymus, spleen and lymph node 
autopsies of pediatric ICU patients with nosocomial sepsis and 
multiple organ failure (117). Toti et al. found a dramatic depletion 
of B and T cells in the spleen of preterm and full-term neonates 
who died of early-onset sepsis due, likely, to in utero infection with 
Gram-positive or -negative microbes (aka. chorioamnionitis) 
(118). These findings indicate that immune effector cell loss during 
sepsis is a universal phenomenon across all age groups.
Apoptosis causes immunosuppression through multiple 
mechanisms. First, severe depletion of B and T cells creates “holes 
in the repertoire” of adaptive lymphocytes. This jeopardizes the 
ability of the immune system to launch highly specific responses to 
pathogens. Furthermore, immunological memory cannot be built 
to protect the survivors at later time points. Apoptosis-mediated 
shrinkage of the DC compartment not only weakens innate 
immunity but also contributes to functional T cell inadequacies 
since naïve T cells can only be primed by DCs. Apoptotic cells 
are immunosuppressive by nature and their uptake by phagocytic 
cells can stimulate the release of anti-inflammatory cytokines 
such as IL-10 (119). In addition, after ingesting apoptotic bod-
ies, DCs may induce death in T cells with which they interact 
or render them anergic (120). The importance of immune cell 
apoptosis in the pathogenesis of sepsis can be underscored by the 
observations that Bcl-2 overexpression or treatment with z-VAD-
fmk, a pan-caspase inhibitor, improves survival in mouse models 
of sepsis (121, 122).
immunotherapy for Sepsis
Advances in our understanding of the pathogenesis of sepsis have 
prompted more than 40 clinical trials of immunotherapeutic 
agents to date. However, the results have been by and large 
disheartening, with many trials yielding no benefits while a few 
even aggravated the syndrome, thus leading to their premature 
termination.
Most previous trials have employed agents that neutralize 
pathogens or their products [e.g., intravenous immunoglobulin 
(123) and the anti-endotoxin antibody nebacumab (124)], 
interfere with pathogen recognition by the host [e.g., the 
TLR4 antagonist eritoran (125)], or target pro-inflammatory 
cytokines/mediators [e.g., the anti-TNF-α antibody afelimomab 
(126) and the recombinant TNF receptor p55–IgG1 Fc fusion 
protein lenercept (127)] or their receptors [e.g., the IL-1 
receptor antagonist anakinra (128) and the platelet-activating 
factor receptor antagonist lexipafant (129)]. Pro-inflammatory 
cytokines sometimes exert redundant functions. Therefore, 
therapeutic approaches targeting individual cytokines are often 
ineffective. Non-specific corticosteroid therapy has also been 
used in sepsis, albeit to little avail (130).
Dampening hyperinflammatory responses may benefit 
some patients in the early phase of sepsis. However, it is now 
recognized that many others have a global cytokine depression 
or even a predominance of anti-inflammatory cytokines. Equally 
important is the fact that most patients rapidly progress to an 
immunosuppressed state associated with a higher susceptibil-
ity to secondary and opportunistic infections, in which case 
weakening the immune system may be counterintuitive. This 
may explain, at least partially, the failure of the vast majority 
of previous trials designed to block inflammatory mediators in 
sepsis. In fact, apart from prophylactic measures and antibiotic 
administration, adjuvant therapy to restore immune competence 
in immunosuppressed septic patients may prove beneficial or 
even lifesaving (99). In an earlier application of such approaches, 
Döcke et  al. administered IFN-γ to a small cohort of septic 
patients whose monocytes had reduced HLA-DR expression 
and whose whole blood cells produced only minute amounts 
of TNF-α in response to LPS stimulation (131). Treatment with 
IFN-γ reversed these deficits and also importantly resulted in 
resolution of sepsis in most cases. In a more recent case report by 
Nalos and coworkers, successful IFN-γ therapy in a male patient 
with type-2 diabetes and prolonged, disseminated S. aureus 
sepsis was documented (132).
Granulocyte-macrophage colony-stimulating factor (GM- 
CSF), a hematopoietic growth factor that stimulates the produc-
tion of neutrophils and monocytes from bone marrow stem cells, 
has also been used and shown promise in immunosuppressed 
septic patients. In a relatively small-scale clinical trial, GM-CSF 
administration was safe and normalized the expression of 
monocytic HLA-DR and shortened the duration of mechani-
cal ventilation and hospital/ICU stay due to sepsis (111). In a 
subsequent study, GM-CSF restored the ex vivo TNF-α produc-
tion capacity of whole blood cells and prevented nosocomial 
infections in pediatric patients with multiple organ dysfunction 
syndrome (133).
IL-7 and IL-15 are two other immune-enhancing cytokines 
with enormous therapeutic potentials. Dubbed as the “maestro 
of the immune system” (134), IL-7 is a pleiotropic cytokine 
with diverse biological properties, some of which may correct 
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immunological abnormalities linked to sepsis. Clinical trials of 
IL-7 in other conditions (e.g., metastatic cancer, HIV-1 infection, 
and progressive multifocal leukoencephalopathy) have demon-
strated that its systemic administration is safe and well tolerated 
(135–137). Furthermore, it seldom causes fever or significant 
pro-inflammatory cytokine production. IL-7 induces naïve and 
memory T cell proliferation without a predilection for Treg cell 
expansion (138). Therefore, its administration could potentially 
replenish the T cell pool following drastic lymphocyte depletion 
in sepsis. IL-7 is known to upregulate the expression of the anti-
apoptotic molecule Bcl-2 in T cells, thus promoting their survival 
(139) and that of cell adhesion molecules (140), thus potentiating 
leukocyte trafficking into the site(s) of infection. In addition, treat-
ment with IL-7 increases the diversity of the TCR repertoire (138, 
139), which in turn improves the breadth of pathogen-specific T 
cell responses. Together, these activities can immensely help com-
bat pathogens during sepsis. The therapeutic benefit of IL-7 has 
been validated in CLP. Using this animal model, Unsinger et al. 
found that recombinant human IL-7 (rhIL-7) can normalize the 
DTH reaction, block T cell apoptosis, restore IFN-γ production, 
and improve host survival (140). Similar results were obtained 
in a “two-hit” model of fungal sepsis in which mice underwent 
CLP to induce peritonitis followed by an intravenous injection of 
Candida albicans (141) to mimic delayed secondary infections 
in ICU patients. Venet et al. reported that IL-7 plasma levels and 
CD127 expression by T lymphocytes remain unaltered in septic 
shock (142). More importantly, T cells from septic patients and 
healthy volunteers exhibited comparable signal transducer and 
activator of transcription 5 (STAT5) phosphorylation and Bcl-2 
upregulation when exposed to rh-IL-7. In addition, rh-IL-7 
augmented T cell proliferation and IFN-γ production by CD8+ T 
cells in response to anti-CD2/CD3/CD28-coated beads that were 
used ex vivo as artificial APCs. Therefore, the IL-7:IL-7 receptor 
machinery appears to be fully operative in septic patients and 
may thus be utilized to reverse their immunological impairments.
IL-15 is another pleotropic cytokine involved in the develop-
ment, maintenance, and proliferative responses of multiple lym-
phocyte lineages. It optimizes effector and memory CD8+ T cell 
functions under normal conditions and also reportedly controls 
the homeostatic recovery of naïve CD8+ T cells after CLP-induced 
sepsis (143). Unlike IL-7, IL-15 is a potent promoter of NK cell 
and DC functions, which can be defective in sepsis. In fact, IL-15 
therapy was demonstrated to block NK cell, DC, and CD8+ T 
cell apoptosis, to increase IFN-γ levels in the circulation, and to 
improve survival of mice rendered septic by the CLP procedure 
or Pseudomonas aeruginosa pneumonia (144). In a recent study, 
septic patients with severe lymphopenia had low expression 
of Bcl-2 mRNA in their peripheral blood mononuclear cells 
despite moderately increased plasma IL-15 concentrations (145). 
Whether such IL-15 quantities are still insufficient and whether 
treatment with exogenous IL-15 may help correct immunological 
incompetence in sepsis warrant further investigation.
Several other studies have focused on blockade of co-inhibitory 
receptors (e.g., PD-1) to alleviate sepsis-induced immunosup-
pression. Since the induced expression of PD-1 on T cells was first 
linked to their exhaustion in the context of chronic viral infection 
(146), interfering with PD-1:PD-L1 interactions has been viewed 
as a tempting therapeutic approach to rejuvenating T cells in vari-
ous conditions including sepsis. Administration of an antagonis-
tic monoclonal antibody (mAb) to PD-1 after the CLP procedure 
rescued the DTH response and prevented the expression loss of 
the pro-survival protein Bcl-xL in splenic T cells (147). This was 
accompanied by a reduction in depletion of lymphocytes and 
DCs and mortality. In a separate study, treatment with an anti-
PD-L1 Ab either before or after CLP led to improved survival of 
septic mice (148). In addition, PD-L1 blockade prevented the loss 
of B and T cells, increased blood levels of IL-6 and TNF-α while 
decreasing IL-10, and lowered bacterial burden in the circulation 
and within the peritoneal cavity. Therefore, the PD-1:PD-L1 axis 
is an attractive target for sepsis immunotherapy.
Tailoring immune intervention strategies to patients’ factors 
and conditions (e.g., age, cytokine profiles, immune competence, 
co-morbidities) and to the phase of sepsis (i.e., early versus pro-
tracted) will improve the likelihood of success (99). Biomarker-
guided, personalized therapies that are carefully timed and 
sufficiently monitored using laboratory and/or clinical measures 
should prevent short- and long-term, adverse consequences of 
sepsis. Agents that block inflammatory cytokines need to be 
short-acting, used in early sepsis, and reserved for a group of 
patients with drastically elevated pro-inflammatory cytokine 
levels. On the contrary, adjuvant immunotherapy will benefit 
septic patients who are in an immunosuppressed state. Failure of 
leukocytes to produce TNF-α in response to LPS stimulation ex 
vivo, subnormal expression of monocytic HLA-DR, upregulated 
expression of PD-1 or PD-L1 on circulating leukocytes, infec-
tions caused by opportunistic pathogens (e.g., Candida spp.) and 
reactivation of otherwise latent viruses, such as cytomegalovirus 
and herpes simplex virus, can help identify such patients.
Animal Models of Sepsis
Using preclinical models that reliably replicate human sepsis is 
essential for the development of novel diagnostic biomarkers, 
prognostic indicators and therapeutic modalities that can be 
truly translatable from the benchtop to the bedside. Common 
animal models of sepsis, which are summarized in Table 1, uti-
lize a variety of septic triggers or insults including LPS injection, 
systemic administration of microbes, surgical disruption of the 
intestinal barrier integrity, and direct introduction of feces into 
the peritoneal cavity.
Clinical and paraclinical (e.g., biochemical) features of sepsis 
serve as guiding principles for the development of bona fide 
animal models and for validation of their relevance to the human 
syndrome. Such models should take into consideration both the 
early hyperinflammatory state, which is characterized by massive 
pro-inflammatory cytokine production and its consequences 
(e.g., fever), and the concurrent or subsequent anti-inflammatory 
responses that contribute to anergy, immunosuppression 
and susceptibility to secondary and opportunistic infections. 
Hemodynamic changes sometimes requiring fluid resuscitation, 
organ damage, apoptotic death of immunocytes, and mortality 
from sepsis also need to be simulated. Animal models should 
also ideally permit therapeutic intervention at defined stages 
of sepsis and efficacy testing of such treatments. Accordingly, 
gross outcome measurements, such as weight loss and death 
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TABLe 1 | Common Animal Models of Sepsis.
Species Model immunopathology and reported manifestations Advantages Disadvantages
Mouse Endotoxicosis
Rapid but transient inflammatory cytokine response, hypotension (149); leukopenia 
(150) hypodynamic cardiovascular changes (151); multi-organ injury, mortality within 
days
Simple and reproducible
Lack of infectious focus; cytokine response magnitude may 
not represent human sepsis (149); poor reflection of complex 
physiological/immunological changes of human sepsis
Systemic  
bacterial 
administration
Rapid but transient inflammatory cytokine response when given i.v., slow and 
sustained inflammatory cytokine response when given i.p. (180); bacteremia, 
hypotension, hypodynamic cardiovascular changes with infected fibrin clot (181); 
multi-organ injury, mortality within hours to days
Simple and reproducible Variability introduced by the choice of bacterial strain 
and administration route; large bolus of bacteria may 
not reproduce changes of human sepsis; may reflect 
endotoxicosis in the case of Gram-negative bacteria
Host barrier 
disruption  
(CLP/CASP)
Rapid pro/anti-inflammatory cytokine response (187) that is more severe in CASP 
vs CLP (201); polymicrobial bacteremia, hypotension, hyperdynamic cardiovascular 
changes (188); T and B cell apoptosis, immunosuppression (189); multi-organ injury, 
mortality within hours to days
Polymicrobial, severity  
controlled by size of puncture/
stent diameter; CLP reproduces 
immunosuppressive phase
Requires surgical techniques; high experimental variability; 
abscess formation may prevent disease development (201)
Feces-induced 
peritonitis (FIP)
Rapid pro/anti-inflammatory cytokine response, systemic bacterial dissemination, 
splenocyte apoptosis (114); hypothermia, impaired metabolism, hypodynamic 
cardiovascular changes (203); mortality within days
Simple, controlled inoculum; 
reflects polymicrobial peritonitis
Microbial dose and composition of the fecal inoculum often 
unknown; cytokine response magnitude more severe vs. 
CLP (206)
Rat Endotoxicosis
Rapid pro/anti-inflammatory cytokine response (152); hypermetabolism, hypotension, 
hypodynamic cardiovascular changes with lethal dose i.v. (153); hyperdynamic 
cardiovascular changes with non-lethal dose i.p. (165); multi-organ injury, mortality 
within hours to days
Simple and reproducible
Lack of infectious focus, poor reflection of complex 
physiological/immunological changes of human sepsis
Systemic  
bacterial 
administration
Rapid pro/anti-inflammatory cytokine response (170); hypotension, bacteremia, 
hypodynamic cardiovascular changes with high dose (171); hyperdynamic 
cardiovascular changes with low dose (177) and infected fibrin clot (185); mortality 
within hours to days
Simple and reproducible, can 
reproduce hyperdynamic  
changes in human sepsis
Large bolus of bacteria may not reproduce changes of 
human sepsis; may reflect endotoxicosis in the case of 
Gram-negative bacteria
Host barrier 
disruption  
(CLP/CASP)
Rapid pro/anti-inflammatory cytokine response (190), hyperdynamic cardiovascular 
changes (191); polymicrobial bacteremia, leukopenia, thrombocytopenia (192); multi-
organ injury, mortality within hours to days
Polymicrobial, severity  
controlled by size of puncture/
stent diameter
Requires surgical techniques; high experimental variability
Rabbit Endotoxicosis Rapid inflammatory cytokine response, hypotension, hypodynamic cardiovascular 
changes with high dose (154); hyperdynamic cardiovascular changes with low dose 
(164); hypothermia, leukopenia (155); multi-organ injury, mortality within hours to days
Simple and reproducible, 
increased sensitivity to LPS 
compared to rodents
More expensive than rodent models; lack of infectious focus, 
poor reflection of complex physiological/immunological 
changes of human sepsis
Systemic 
bacterial 
administration
Rapid inflammatory cytokine response, hypotension, leukopenia, thrombocytopenia 
(172); bacteremia, hypothermia, neutrophil apoptosis (182); multi-organ injury, 
mortality within hours
Simple and reproducible
More expensive than rodent models; less well-
characterized; may reflect endotoxicosis in the case of 
Gram-negative bacteria
Pig Endotoxicosis Rapid pro/anti-inflammatory cytokine response, neutropenia, lymphopenia (156); 
hypotension, DIC, hypodynamic cardiovascular changes (157); hyperdynamic 
cardiovascular changes with fluid resuscitation (160); mortality within hours
Simple, reproducible, porcine 
physiology and LPS sensitivity 
similar to humans
Expensive housing and care costs; lack of infectious focus; 
poor reflection of complex physiological/immunological 
changes of human sepsis
Systemic 
bacterial 
administration
Rapid pro/anti-inflammatory cytokine response, bacteremia, DIC (173); hypotension, 
hypodynamic cardiovascular changes (174); multi-organ injury, mortality within hours 
to days
Simple, reproducible, porcine 
physiology similar to humans
Expensive housing and care costs; large bolus of bacteria 
may not reproduce changes of human sepsis; may reflect 
endotoxicosis in the case of Gram-negative bacteria
Feces-induced 
peritonitis (FIP)
Inflammatory cytokine response, hypotension, hyperdynamic cardiovascular  
changes with fluid resuscitation (204, 205); leukocytosis, endotoxemia (174); multi-
organ injury, mortality
Porcine physiology similar to 
humans; reflects polymicrobial 
peritonitis
Expensive housing and care costs; microbial dose and 
composition of the fecal inoculum often unknown
Non-
Human 
Primate
Endotoxicosis
Rapid but transient pro-inflammatory cytokine response, hypotension, hypodynamic 
cardiovascular changes (158); thrombocytopenia, leukopenia (159)
Cross-reactivity with human 
thera-peutics and diagnostic 
tools, most comparable to 
human physiology
Most expensive housing and care costs; ethical concerns; 
more accurately reflects human endotoxicosis rather than 
sepsis
Systemic  
bacterial 
administration
Rapid pro/anti-inflammatory cytokine response, hypotension, leukopenia, 
thrombocytopenia, DIC (175); hypodynamic cardiovascular changes that become 
hyperdynamic with fluid resuscitation (176); multi-organ injury, mortality within  
hours to days
Cross-reactivity with human 
therapeutics and diagnostic tools, 
most comparable to human 
physiology
Most expensive housing and care costs; ethical concerns; 
may reflect endotoxicosis in the case of Gram-negative 
bacteria
CASP, colon ascendens stent peritonitis; CLP, cecal ligation and puncture; DIC, disseminated intravascular coagulation; FIP, feces-induced peritonitis; i.p., intraperitoneal; i.v., intravenous; LPS, lipopolysaccharide.
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rates, should be complemented with laboratory assessments of 
immune competence or incompetence (e.g., cytokine production 
and anergy/exhaustion marker expression).
Findings from models in which young, adult and otherwise 
healthy animals are utilized may not accurately represent the 
“real-life” features of sepsis in the rising elderly populations. This 
is a major limitation of animal models that place a dispropor-
tionate emphasis on sepsis-induced hyperinflammation, which 
no longer accounts for most deaths due to sepsis at least when 
advanced ICU facilities and robust practice of critical care are in 
place. Therefore, experimentation with older animals and those 
with co-morbidities may provide a more realistic picture of sepsis 
in vulnerable populations.
One of the most routinely utilized agents to induce sepsis in 
small and large animals is LPS (149–160), a glycolipid found 
abundantly in the outer membrane of Gram-negative bacteria. 
Following intravenous (i.v.) or intraperitoneal (i.p.) injection, 
LPS binds to the glycosylphosphatidylinositol (GPI)-anchored 
protein CD14 and signals through TLR-4 to provoke a systemic 
inflammatory response often referred to as “endotoxicosis” 
(161, 162). This response is characterized by pro-inflammatory 
cytokine production, multiple organ injury and hypotensive 
shock, which are hallmarks of early sepsis. LPS administration 
is simple and does not require advanced surgical techniques. 
In addition, its dosage can be easily controlled. However, one 
should keep in mind that exposure to large amounts of LPS may 
result in an immediate hypodynamic cardiovascular state that 
does not represent human sepsis (163). Several groups have 
overcome this problem by developing models that use sublethal 
doses of LPS (164, 165) or aggressive fluid resuscitation (166). 
Also importantly, bolus injection of LPS into laboratory animals 
triggers a severe inflammatory cytokine response that differs 
in magnitude and sustenance from what is observed in clinical 
sepsis (163, 167).
Lethal shock and disseminated intravascular coagulation 
(DIC) can be induced in mice by two consecutive injections of 
LPS separated by a 24-h interval (168). In this model, which is 
known as “generalized Shwartzman reaction,” a “super low” dose 
of LPS is injected followed by a larger systemic dose that elicits 
rapid pro- and anti-inflammatory responses, coagulopathy and 
multi-organ damage. It is noteworthy that the initial prim-
ing dose in Shwartzman reaction is smaller than that causing 
endotoxin tolerance (169). It is believed that tolerizing doses of 
LPS activate the canonical nuclear factor-κB (NF-κB) pathway 
leading to robust expression of pro-inflammatory mediators as 
well as a myriad of suppressive elements designed to prevent 
progressive inflammation (169). In contrast, super low doses of 
LPS, such as those used in the priming phase of Shwartzman 
reaction, fail to activate the NF-κB pathway. Instead, they trigger 
the activation of CCAAT/enhancer binding protein δ (C/EBPδ) 
in an IL-1 receptor-associated kinase 1 (IRAK1)-dependent 
manner resulting in mild but persistent expression of inflamma-
tory mediators (169).
All animal models of endotoxicosis lack an infectious focus. 
In addition, since LPS is only present in Gram-negative bacteria, 
these models do not represent polymicrobial sepsis caused by 
mixed Gram-positive and Gram-negative microbes.
Systemic administration of a large number of bacteria, typi-
cally E. coli, instigates a massive inflammatory cytokine response, 
cardiovascular collapse and rapid mortality (170–175). Fluid 
resuscitation or sublethal dosages of bacteria can be used to better 
mimic the septic response and its hemodynamic manifestations 
in humans (176–178). These models allow for bacterial strains 
and numbers to be carefully chosen and for host responses to 
develop against intact microbial pathogens. However, they are 
more similar to models of endotoxicosis than full-blown infec-
tions when Gram-negative bacteria are used. Many bacterial 
strains are complement-sensitive and lysed shortly after they 
enter the circulation, thus releasing their endotoxin content (179). 
Moreover, systemic bacterial infusion gives rise to serum TNF-α 
concentrations that are orders of magnitude larger than those 
found in septic patients or in peritonitis models (179). Lastly, 
the route of administration can impact the vigor of the septic 
response. For instance, a robust but transient TNF-α response is 
elicited following an i.v. challenge of mice with live E. coli O111, 
whereas an i.p. challenge leads to much lower but more sustained 
blood levels of TNF-α (180).
Surgical implantation of bacteria (e.g., E. coli)-laden fibrin 
clots into the peritoneum has also been used to induce sepsis in 
several species (181–185). Some of these models more accurately 
reproduce the hyperdynamic state and slow, sustained release of 
cytokines associated with human sepsis.
Cecal ligation and puncture (CLP) is considered by many 
as the “gold standard” of intra-abdominal sepsis models. This 
relatively simple surgical procedure involves a laparotomy and 
ligation of the cecum in a non-obstructing manner followed 
by puncturing the ligated portion to allow fecal content to leak 
into the otherwise sterile peritoneal cavity (186). Therefore, a 
source of necrotic tissue combined with an infectious focus that 
persistently challenges the host with enteric microbes causes 
polymicrobial sepsis. CLP-inflicted sepsis resembles the clinical 
syndrome since it can set in motion a systemic pro-inflammatory 
cytokine response as well as a compensatory anti-inflammatory 
response and a hyperdynamic cardiovascular state (162, 187–192). 
Furthermore, CLP is particularly useful for studying the delayed 
phase of sepsis in which immune responses are impaired. This is 
possible by the “two-hit” versions of the model, in which mice 
undergo CLP and are subsequently challenged with a secondary/
opportunistic pathogen, such as Streptococcus pneumoniae (193), 
Pseudomonas aeruginosa (193–195), Candida albicans (141) or 
Aspergillus fumigatus (196). Logistically, the CLP procedure is 
quick to perform by an experienced experimentalist. It can also 
be readily modified to investigate varying degrees of inflamma-
tion and different survival intervals. The length of ligated cecum 
(197), the size of the needle used for the perforation (198), and 
the number of punctures made (199) can all determine the sever-
ity of sepsis and the speed with which death occurs. It needs to be 
noted that the CLP outcome may vary considerably among dif-
ferent laboratories and animals depending upon the experimen-
talist’s surgical expertise and the animals’ sex, age, strain, housing 
conditions, cecal content, and even cecal fullness when CLP is 
performed (167). Another disadvantage of the CLP model lies in 
the host’s natural ability to form an abscess in order to contain 
infection (200, 201). Therefore, treatments that promote abscess 
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formation may improve survival in CLP, which may introduce 
bias by adding a confounding variable in the experiment.
Another model of host barrier disruption leading to sepsis 
is colon ascendens stent peritonitis (CASP), in which a stent is 
inserted into the ascending colon to allow for leakage of fecal 
matter into the peritoneal cavity (201, 202). Although similar to 
CLP in principle, CASP represents persistent peritoneal infec-
tion rather than abscess formation and causes a more robust 
cytokine response and higher bacterial loads within several 
organs. The severity of and mortality from CASP are influenced 
by the diameter of the stent and also by its removal at defined 
time points. This mimics surgical interventions to eliminate 
infectious foci in humans.
Host barrier disruption models are heavily reliant on surgical 
techniques and relatively difficult to standardize. An alternative 
approach is to simply inject animals with a given amount of fecal 
solution i.p. (114, 174, 203–205). This is called the feces-induced 
peritonitis (FIP) model of polymicrobial sepsis, for which we 
recently developed a robust scoring system (114). Early inflam-
matory cytokine production in FIP is typically much more intense 
than that caused by CLP (206). The amount of feces to be injected 
i.p. can be adjusted to alter the severity and outcome of sepsis. An 
additional advantage of FIP is that fecal solutions with identical 
microbial loads and composition can be injected into multiple 
recipient cohorts. This is in contrast with barrier disruption 
models requiring the leakage of each animal’s intestinal content 
into the peritoneal cavity, which is an inevitable source of varia-
tion. A limitation of the FIP model is that the dosage and species 
of bacteria introduced into the recipients are usually unknown 
given that intestinal flora vary according to the animal strain, 
commercial source and housing conditions. Finally, the state of 
immunosuppression that follows the hyperinflammatory phase 
of sepsis has not been fully characterized in FIP.
Despite the abundance of animal models for sepsis, there is 
currently no one truly clinically relevant model that fully reca-
pitulates all the complex immunological, hemodynamic, and 
pathophysiological responses seen in human sepsis. The reason 
for outcome discrepancies between animal models and clinical 
sepsis is multifactorial, but partially stems from the heterogeneity 
of patient populations. Nevertheless, we continue to rely on cur-
rent animal models and strive to come up with improved models 
in order to better understand the pathogenesis of sepsis and to 
design and test novel treatments for this fatal syndrome.
iNKT Cells and Sepsis
Several groups including ours have explored the effector or 
regulatory capacities of iNKT cells and their synthetic glycolipid 
agonists in sepsis and endotoxic shock.
Rhee et al. from Alfred Ayala’s laboratory first reported that 
treating 129S1/SvImJ mice with an anti-CD1d mAb (clone 1B1) 
before the CLP surgery could reduce plasma and splenic IL-6 
and IL-10 levels and prevented sepsis-induced mortality in some 
of the treated mice (207). They also noted a significant increase 
in the frequency of cell populations co-expressing T and NK 
cell markers, which could be reversed by anti-CD1d treatment. 
It needs to be noted that although the 1B1 mAb has been used 
extensively to block CD1d interactions with NKT cell TCRs, it 
may also potentially activate CD1d+ APCs (208). Therefore, the 
mechanism of action of this mAb could not be definitively deter-
mined. More importantly, both iNKT and vNKT cells interact with 
CD1d (50). We now know that there are other CD1d-restricted T 
cell types such as a subpopulation of γδ T cells (209) that can be 
affected by anti-CD1d treatment. Nevertheless, the study of Rhee 
et al. indicated a role for CD1d-restricted T cells in sepsis and set 
the stage for subsequent important investigations.
Hu et  al. extended the above study to other mouse strains 
(210). They demonstrated that pre-treatment of BALB/c mice 
with 1B1 before CLP confers upon them a survival advantage. 
This treatment also prevented the rise in circulating levels of 
TNF-α, IL-6, monocyte chemotactic protein (MCP)-1 and IL-10. 
Within the liver, mice receiving 1B1 had lower frequencies of NKT 
cells capable of producing TNF-α, IL-6, IL-4 or IL-10, indicating 
no bias toward either a pro- or anti-inflammatory phenotype. 
Interestingly, however, the percentage of IL-6-producing hepatic 
macrophages declined whereas that of IL-10-producing cells 
increased upon anti-CD1d treatment. How CD1d contributes 
to the immunopathology of sepsis is not clear. It is possible that 
lipid antigens derived from bacterial pathogens are loaded into 
CD1d and presented to NKT cells. Alternatively or in addition, 
recognition of pathogen-associated molecular patterns (PAMPs) 
by PRRs such as TLRs may lead to the production of IL-12 and 
IL-18 by APCs during sepsis. Once coupled with CD1d-mediated 
presentation of endogenous lipids, these cytokines can induce 
NKT cell activation (42, 43). Sepsis-induced tissue injury may 
also increase, release and/or modify endogenous lipids that can 
be displayed by CD1d to trigger NKT cell responses (Figure 1). 
Consistent with this hypothesis, a previous study reported that 
serial injections of apolipoprotein E (ApoE), a component of 
plasma lipoproteins, alters NKT cell compartments and increases 
CLP-induced mortality in rats (211).
Hu et al. also used the CLP model to examine the contribu-
tion of the invariant subset of NKT cells to sepsis (210). They 
found a marked decline in the frequency of hepatic iNKT cells, 
defined by their reactivity with α-GalCer-loaded CD1d tetramer, 
in both C57BL/6 and BALB/c mice. This was accompanied by 
upregulation of CD69 and CD25 on the surface of iNKT cells 
indicating their enhanced activation on a per cell basis. There 
exist several possibilities to explain the lower percentage of 
detectable iNKT cells in the liver of septic mice. These include 
iTCR internalization, which is a well-known phenomenon in the 
context of iNKT cell activation by synthetic glycolipids (212), cell 
death in situ, or migration to other locations. To address these 
possibilities experimentally, one could assay for intracellular 
iTCRs or quantify mRNA corresponding to the Vα14–Jα18 TCR 
rearrangement in hepatic non-parenchymal cells, or track iNKT 
cell movements in the body.
To ascertain whether iNKT cells play a pathogenic or 
protective role in sepsis, Hu and coworkers used Jα18−/− 
mice that lack iNKT cells (210). These animals exhibited 
reduced mortality due to CLP as well as ablated TNF-α, 
IL-6, MCP-1 and IL-10 systemic responses in comparison 
with wild-type C57BL/6 mice. It was recently found that the 
TCRα repertoire of Jα18−/− mice that have been widely avail-
able to the research community is shrunk by ~60% (213). 
August 2015 | Volume 6 | Article 40112
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
FiGURe 1 | iNKT cell activation pathways in sepsis. Early in the course of 
the host response to bacterial pathogens involved in sepsis, the engulfment of 
these microbes by phagocytic cells generates pathogen-derived glycolipids that 
can be displayed by CD1d to induce iNKT cell activation. Phagocytic cells that 
have taken up bacteria and/or sensed PAMPs (e.g., LPS) through PRRs (e.g., 
TLR-4) secrete inflammatory cytokines. Some of these cytokines (e.g., TNF-α, 
IL-1, IL-6) are responsible for clinical manifestations of sepsis, while others (i.e., 
IL-12 and IL-18) can activate iNKT cells. The latter pathway often, but not 
always, requires CD1d-mediated presentation of endogenous glycolipids to 
iNKT cells. SAg-secreting bacteria, such as Staphylococcus spp. and 
Streptococcus spp. participating in Gram-positive bacterial sepsis, can directly 
activate iNKT cells. It is possible that bacterial PAMPs may be detected by iNKT 
cells. Finally, during or as a result of the septic insult, host cell damage leads to 
release and/or modification of endogenous glycolipids that can be potentially 
presented by CD1d to trigger iNKT cell activation in an iTCR-dependent 
manner. Once activated, iNKT cells produce pro-inflammatory cytokines, most 
notably IFN-γ that plays a pivotal role in sepsis-inflicted immunopathology. APC, 
antigen-presenting cell; CD, cluster of differentiation; DC, dendritic cell; IFN, 
interferon; IL, interleukin; iNKT, invariant natural killer T cell; iTCR, invariant T cell 
receptor; LPS, lipopolysaccharide; MHC, major histocompatibility complex; 
PAMP, pathogen-associated molecular pattern; PRR, pattern recognition 
receptor; TLR, Toll-like receptor.
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Therefore, the cellular deficiency in Jα18−/− mice is not exclusive 
to iNKT cells, which necessitates iNKT cell reconstitution 
experiments to validate results obtained using these animals.
More recently, Heffernan et al. demonstrated that while CLP 
causes a drop in the frequency of iNKT cells in the liver, both 
the absolute number of iNKT cells and their frequency among 
T lymphocytes are elevated in the circulation and within the 
peritoneal cavity, which is considered the site of polymicrobial 
infection in this model (214). Furthermore, a much bigger frac-
tion of peritoneal iNKT cells expressed CD69 in septic mice in 
comparison with the sham laparotomy control group. Although 
iNKT cell mobilization by CLP was not directly monitored, 
these results support the scenario in which iNKT cells migrate 
out of the liver and toward the source of infection, which should 
account for their decline in the liver. Intriguingly, this migra-
tion was mediated by PD-1, which is well known as an anergy/
exhaustion marker. Following sepsis, PD-1−/− mice exhibited a 
numerical increase in activated hepatic iNKT cell populations but 
intact peripheral blood or peritoneal iNKT cell compartments 
when they were compared with the sham controls. Whether the 
role of PD-1 in iNKT cell migration is intrinsic to these cells was 
not studied. This question could be addressed by reconstitution of 
Jα18−/− mice with PD-1-sufficient or -deficient iNKT cells prior to 
the CLP procedure. These investigators also found that once accu-
mulated in the peritoneal cavity, iNKT cells influence the ability 
of local macrophages to phagocytose bacteria and clear infection. 
Bacterial load in the cavity was lower in septic Jα18−/− mice than in 
wild-type controls. In addition, peritoneal macrophages derived 
from septic Jα18−/− mice were more potent than those from septic 
wild-type animals in engulfing E. coli. Collectively, the work of 
Heffernan and coworkers reveals an interesting interplay between 
migrant iNKT cells and macrophages residing within foci of 
infection during sepsis. It also suggests that blockade of PD-1 
may not only reverse T cell exhaustion to relieve sepsis-induced 
immunosuppression but also likely benefits the host by modu-
lating the migration capacity of iNKT cells to further facilitate 
microbial clearance.
Taken together, the above studies indicate a pathogenic role 
for iNKT cells in CLP-induced sepsis. Several groups have 
reached the same conclusion using animal models of LPS-
inflicted pathology or lethality. Koide et  al. established a link 
between the resistance of d-galactosamine (d-GalN)-sensitized 
NC/Nga mice to LPS and the presence of fewer NKT cells in 
these animals (215). This old protocol utilizes the hepatotoxic 
agent d-GalN to sensitize laboratory animals to very low doses 
of LPS, and has been used extensively as a model of endotoxic 
shock and Gram-negative microbial sepsis. We are of the opin-
ion that the d-GalN sensitization model simulates acute hepatic 
failure more closely. Nevertheless, participation of inflammatory 
mediators is evident in its immunopathology amid severe liver 
damage. While co-administration of d-GalN and LPS led to 
100% mortality in C57BL/6 mice within 12  h, it failed to kill 
NC/Nga mice even at 24  h (215). It also raised the activity 
level of alanine aminotransferase (ALT) in the serum and that 
of caspase-3 in the liver extract of C57BL/6 mice but not NC/
Nga mice (216). Moreover, drastic lesions with hemorrhage and 
many apoptotic cells were observed in C57BL/6 but not in NC/
Nga liver sections. NC/Nga mice injected with d-GalN and LPS 
had negligible levels of  IFN-γ protein in their serum or IFN-γ 
mRNA in their liver. This was accompanied by a 10-fold reduc-
tion in the size of CD3ϵ+DX5+ NKT cell compartment in the 
liver although NKT cells were capable of producing ample IFN-γ 
on a per cell basis. Finally, administration of recombinant IFN-γ 
to d-GalN-sensitized NC/Nga mice rendered them susceptible 
to LPS-induced  mortality. In this body of work, frequency analy-
ses were  performed on NKT cells co-expressing T and NK cell 
markers. However, iNKT cells are the likely culprits and the early 
 triggers of pathology in d-GalN/LPS-prone mice. This is because 
iNKT cells comprise the vast majority of hepatic NKT cells in 
mice (217). Second, when Koide and coworkers injected NC/
Nga mice with the iNKT cell superagonist α-GalCer a few hours 
before the d-GalN/LPS challenge, endogenous IFN-γ production 
was restored leading to increased expression of inducible nitric 
oxide synthase (iNOS), appearance of apoptotic cells in the liver, 
and 100% mortality (215). It was therefore concluded that the 
 resistance of NC/Nga mice to the LPS-mediated lethality with 
d-GalN sensitization is due to impaired IFN-γ production caused 
by a shortage of iNKT cells and reduced nitric oxide  production 
in these animals. An additional confirmatory approach would 
have been to adoptively transfer a large number of syngeneic 
iNKT cells into NC/Nga mice to increase their frequency before 
testing the susceptibility of the recipients to d-GalN/LPS.
In a different model of endotoxic shock, α-GalCer injection 
sensitized wild-type mice, but not Jα18−/− mice, to LPS-mediated 
lethality (218). Interestingly, shock in these animals was accom-
panied by severe lesions and hemorrhage, marked accumulation 
of polymorphonuclear leukocytes and mononuclear cells, and 
significant cell death almost exclusively in the lungs. Although 
serum ALT levels were elevated, hepatic lesions were focal and 
mild, and other organs showed no signs of overt injury or other 
changes except for congestion. Pulmonary manifestations and 
lethal shock in this model could not be induced by simultaneous 
administration of α-GalCer and LPS, and required an interval 
period of 3–24  h between α-GalCer sensitization and the LPS 
challenge. This is consistent with the kinetics of IFN-γ secretion 
in response to α-GalCer, which is potentiated by iNKT cells and 
largely contributed by transactivated NK cells (219). Ito et  al. 
found that α-GalCer injection gives rise to high blood levels of 
IFN-γ within the above timeframe and augments the subsequent 
production of TNF-α, a major mediator of endotoxic shock, in 
response to LPS (218). They further demonstrated that neutral-
izing IFN-γ or genetic deficiency of TNF-α abolishes the systemic 
lethal shock in this model. Therefore, it was proposed that IFN-γ 
and TNF-α play pivotal roles in preparation and execution of 
LPS-mediated lethality, respectively, in α-GalCer-primed mice. 
Following up on these findings, Tumurkhuu et  al. found that 
priming with α-GalCer increases the frequency of NKT cells 
among pulmonary non-parenchymal leukocytes and induces 
local IFN-γ production (220). This resulted in expression of 
several adhesion molecules, most notably vascular cell adhesion 
molecule-1 (VCAM-1), on vascular endothelial cells of the lungs, 
which in turn promoted the accumulation of very late activat-
ing antigen-4 (VLA-4)+ cells among inflammatory cell recruits 
in the lungs. This was significant because an anti-VCAM-1 
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mAb partially averted LPS-mediated lethal shock in α-GalCer-
sensitized mice.
In the above studies, the relative contributions of iNKT and 
NK cells to IFN-γ production was not determined. There cur-
rently exists no commercially available antibody for selective 
depletion of iNKT cells although online literature search through 
the World Wide Web indicates that a mAb called NKT14 may 
serve this purpose in the future. Until this or similar antibodies 
become available, one could employ anti-asialo GM1 antiserum 
and an anti-NK1.1 mAb (clone PK136) in parallel cohorts of mice 
to address this question. The former depletes NK cells without 
affecting the NKT cell population, and the latter depletes both 
NK and NKT cells (45, 221).
Another important question is why LPS-induced pathology 
in α-GalCer-sensitized mice is restricted to the lungs while the 
liver is largely spared. This is particularly interesting in light of 
the observation that α-GalCer induces IFN-γ production by 
both hepatic and pulmonary iNKT cells and that IFN-γ is read-
ily detectable at mRNA and protein levels in both organs. It has 
been argued that IFN-γ signaling is fully operational in the lungs 
but not in the liver of α-GalCer-primed mice (222). Augmented 
expression of phosphorylated STAT1 was more sustained in the 
lungs than in the liver. In addition, IFN regulatory factor 1 (IRF1) 
was upregulated in the lungs but not in the liver of α-GalCer-
treated mice. Second, pulmonary NKT cells reportedly produce 
IFN-γ as their main cytokine, whereas hepatic NKT cells produce 
IFN-γ, IL-4 and IL-10. Neutralization of IL-4 enhances STAT1 
activation, exacerbates the hepatic injury, and increases the 
number of apoptotic cells in the liver. Therefore, IL-4 has been 
proposed to inhibit IFN-γ signaling in the liver while its absence 
promotes IFN-γ-mediated pathology in the lungs (222). Finally, 
one might wonder why a potentially similar mechanism is not at 
play to protect NC/Nga livers in the d-GalN/LPS model (215). 
It is possible that the cytokine profile of α-GalCer-primed NC/
Nga mice differs from that of C57BL/6 and BALB/c mice. The 
hepatotoxic nature of the d-GalN insult may also mask the influ-
ence of other factors involved. These possibilities are not mutually 
exclusive.
Several studies have focused on the role of iNKT cells in sys-
temic Shwartzman reaction. IFN-γ is considered a key cytokine 
in the pathogenesis of Shwartzman reaction because it induces 
massive production of TNF-α, IL-1 and other inflammatory 
mediators. Dieli et al. found Jα18−/− mice on either C57BL/6 or 
BALB/c background to be resistant to the LPS-induced mortality 
of Shwartzman reaction (223). Jα18−/− mice had lower serum 
levels of IFN-γ and TNF-α in comparison with wild-type ani-
mals, and administration of recombinant IFN-γ was sufficient 
to prime these animals. In two more recent studies, Sierci et al. 
tested the effect of α-GalCer treatment at different time points 
before or after LPS priming (224, 225). When α-GalCer was 
given approximately 6, 9, or 12 days prior to the first injection 
of LPS, mice survived the subsequent LPS challenge and their 
protection was associated with reduced serum levels of IFN-γ 
and TNF-α and hepatic level of MCP-1 (224). In stark contrast, 
when administered 1 or 3 days before priming, α-GalCer failed 
to protect the mice from lethal endotoxic shock. It appears likely 
that earlier α-GalCer injection induces iNKT cell anergy (226), 
thus hampering their IFN-γ production capacity. It would be 
interesting to examine the expression level of PD-1 on iNKT cells 
obtained from α-GalCer-pretreated mice or to test whether block-
ade of the PD-1:PD-L1 interaction restores Shwartzman reaction. 
In a separate study, Sierci et al. found that α-GalCer administered 
within 2  h before or after the LPS challenge rescues the mice 
(225). This timeframe is consistent with the period in which IL-4 
production by α-GalCer-stimulated iNKT cells reaches its peak 
while only minute amounts of IFN-γ are detectable in the serum. 
Accordingly, Sierci and coworkers noted increased IL-4 and IL-10 
responses and decreased levels of IFN-γ and TNF-α in protected 
mice. In addition, blood levels of ALT and aspartate aminotrans-
ferase (AST) were lower in these animals indicating milder injury 
to the liver. The beneficial effect(s) of Th2-type cytokines were 
confirmed when mice receiving either an anti-IL-4 or an anti-
IL-10 mAb succumbed to endotoxic shock. Therefore, inducing 
Th2-skewed iNKT cell responses may have potential therapeutic 
applications in sepsis. We recently put this hypothesis to the test 
by using Th2-promoting iNKT cell agonists in the FIP model of 
sepsis (read below).
In a prospective study, we demonstrated that patients with 
sepsis have a significantly elevated ratio of peripheral blood 
iNKT:T cells in comparison with non-septic trauma patients 
(37). The patient cohorts were similar in age and in severity of 
illness that was calculated based on their Acute Physiology and 
Chronic Health Evaluation II (APACHE II) scores in the initial 
24-h period post-diagnosis (227). Next, we compared wild-type 
and Jα18−/− mice receiving a fecal slurry i.p. for severity of FIP 
using a murine sepsis score (MSS) that we recently developed 
(114) and also for mortality from sepsis. The severity of sepsis 
was significantly lower in Jα18−/− mice than in wild-type controls. 
In addition, intra-abdominal fecal challenge resulted in 100% 
mortality in wild-type animals but no death in septic Jα18−/− mice 
within 24  h. Importantly, reconstitution of Jα18−/− mice with 
iNKT cells before the septic insult increased the severity of their 
symptoms. Together, these results confirm the pathogenic nature 
of iNKT cells in the FIP model. In the next series of experiments, 
we explored the therapeutic potentials of OCH, a Th2-polarizing 
analog of α-GalCer (34), in FIP. We found that a single i.p. injec-
tion of OCH within 20 min after the fecal challenge reduced the 
MSS scores and prolonged the survival of septic mice compared 
with vehicle- or α-GalCer-treated animals. These changes were 
associated with elevated blood levels of the Th2-type cytokine 
IL-13 and reduced levels of the pro-inflammatory cytokine IL-17. 
Furthermore, OCH treatment decreased the number of apoptotic 
T cells, B cells and macrophages in the spleen. Anti-inflammatory 
mechanisms are known to contribute to sepsis-induced immu-
nosuppression, which may make a septic individual susceptible 
to opportunistic infections (93). Therefore, we asked whether 
OCH treatment worsens the microbial load in septic mice. Much 
to our satisfaction, this was not the case, and blood and tissue 
homogenates prepared from the heart, lungs, kidneys, liver and 
spleen of vehicle-, OCH- and α-GalCer-treated septic mice 
had comparable numbers of microbial colony-forming units. 
Finally, administration of C20:2, another glycolipid that is even 
more potent than OCH in inducing a Th2 bias (228, 229) and 
that additionally suppresses downstream NK cell function (230), 
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also mitigated the severity of FIP-induced sepsis. However, this 
effect was only transient, which may be explained by the relatively 
short half-life of C20:2 compared with OCH (228, 230). Based 
on these results, we propose that Th2-skewing agonists of iNKT 
cells may be employed to treat the hyperinflammatory phase of 
sepsis without compromising the patient’s immunity to microbial 
pathogens.
Finally, during polymicrobial sepsis, common bacterial patho-
gens, such as Staphylococcus spp. and Streptococcus spp., are likely 
to release the SAgs they harbor (Figure 1). We recently discov-
ered that staphylococcal and streptococcal exotoxins belonging 
to phylogenetic group II SAgs can directly activate mouse and 
human iNKT cells leading to IFN-γ production (45). However, 
anticipating the net effect is not simple because: (i) the type of 
microbial pathogens involved in sepsis may vary substantially 
among different individuals; (ii) how multiple SAgs released by 
multiple bacterial pathogens may cross-regulate the response 
to each other is far from clear; (iii) host responses to SAgs may 
be modulated by cell wall components of the very bacteria that 
release SAgs as we previously described (231).
To summarize, the studies highlighted in this section all point 
to a pathogenic role for iNKT cells in sepsis regardless of the 
experimental model employed, and IFN-γ is a major mediator of 
iNKT cell-inflicted damage in this context.
vNKT Cells and Sepsis
The extent to which vNKT cells contribute to or regulate sepsis 
is unknown. However, in vivo treatment with sulfatide, a CD1d-
restricted ligand of vNKT cells, has been demonstrated to attenu-
ate the magnitude of the septic response, thus providing indirect 
evidence for a protective role of activated vNKT cells in sepsis.
The beneficial effect of sulfatide was initially noted in two 
relatively old studies on LPS-induced sepsis with a focus on 
how this glycolipid influences leukocyte adhesive properties and 
transendothelial migration as opposed to NKT cell functions 
(232, 233). Higashi et al. reported that while 75% of C3H/HeN 
mice died within 2 days of injection with a large dose of LPS, only 
20% of mice that were pretreated with bovine brain-extracted 
sulfatide succumbed even after 7  days (232). Administration 
of sulfatide to either C3H/HeN or C57BL/6 mice also partially 
inhibited their TNF-α response to a sublethal dose of LPS. Finally, 
using a mouse model of endotoxin-induced hypotension, these 
investigators demonstrated that treatment with sulfatide prior to 
the LPS challenge prevents an otherwise progressive decline in 
systolic blood pressure. Squadrito and coworkers explored the 
effect of sulfatide on acute lung injury in a rat model of endotoxic 
shock (233). When administered shortly after the LPS injection, 
sulfatide was able to partially offset hypotension, revert leukope-
nia, and diminish myeloperoxidase activity in the lungs that was 
used as an indication of neutrophil accumulation in this tissue. 
Also importantly, sulfatide treatment caused a near complete 
prevention of LPS-induced lethality.
The only published report to date addressing a link between 
CD1d-restricted, sulfatide-reactive T cells and sepsis has utilized 
an experimental mouse model of S. aureus infection (234). In 
this work, Kwiecinski et al. found that TCRβ+NK1.1+α-GalCer/
CD1d tetramer− cells, which should contain a sizeable population 
of vNKT cells, have an activated phenotype as judged by their 
upregulated expression of CD69 in infected mice. They also 
showed that treating wild-type C57BL/6 mice with porcine 
sulfatide before bacterial inoculation lowers their blood levels of 
TNF-α and IL-6 without altering the staphylococcal burden in 
blood, liver or kidneys. Therefore, sulfatide treatment does not 
impede the ability of the immune system to combat this pathogen. 
In fact, wild-type mice receiving sulfatide 1 h before and 3 days 
after bacterial inoculation were partially protected. Importantly, 
the survival advantage conferred by sulfatide treatment could be 
recapitulated in Jα18−/− (vNKT-sufficient, iNKT-deficient) mice 
but was missing in CD1d−/− (vNKT- and iNKT-deficient) mice. 
The significance of this finding is two-fold. First, it strongly sug-
gests that activated vNKT cells mediate the protective effect of 
sulfatide in septic wild-type mice. Second, unlike in other models 
where sulfatide treatment induces iNKT cell anergy to ameliorate 
inflammation and injury (235, 236), its beneficial effect in S. aureus 
sepsis does not require the presence of iNKT cells. Of note, late 
injection of sulfatide in this model (i.e., on day 3 post-bacterial 
inoculation) failed to improve survival. This may be viewed as an 
impediment to the possibility of sulfatide therapy in staphylococ-
cal sepsis once the symptoms have developed. However, more 
comprehensive studies are warranted to possibly find a window 
of opportunity during which sulfatide-based interventions may 
be effective in staphylococcal and other forms of sepsis.
MAiT Cells and Sepsis
MAIT cells are relatively frequent among human innate-like T 
cells and capable of responding to a wide variety of bacterial and 
fungal pathogens. The ability of MAIT cells to rapidly produce 
inflammatory cytokines, together with their strategic positioning 
at the host–pathogen interface, makes them an ideal candidate 
to fulfill the role of emergency responders to infection and/or 
regulators of the septic response.
Grimaldi et al. recently explored how sepsis may change the 
frequency and absolute number of MAIT cells in the circulation 
(237). In a prospective study, they recruited a relatively large 
number of patients with severe sepsis or septic shock and com-
pared their peripheral blood MAIT, iNKT, and γδ T cell compart-
ments with those of critically ill patients with non-septic (mostly 
cardiogenic) shock, and age-matched healthy volunteers. Septic 
patients exhibited an early and dramatic decrease in their MAIT 
cell count compared with non-infected critically ill patients or 
healthy controls. This was unlike iNKT or γδ T cell counts that 
remained unaltered in different groups. Also interestingly, there 
was no association between MAIT cell and total lymphocyte 
counts, suggesting that MAIT cells follow an independent kinetic 
pattern in sepsis. By the same token, the frequency of MAIT cells 
among CD3+TCRγδ− conventional T cells was significantly lower 
in septic patients than in healthy subjects.
The above investigation also led to other potentially important 
observations. First, the early drop in MAIT cell frequencies was 
more pronounced in septic patients with non-streptococcal 
infections than in those with streptococcal infections. In addi-
tion, in a small cohort of patients with severe viral infections in 
the absence of concomitant bacterial infections, MAIT cell values 
were similar to those of healthy controls. Streptococcus spp. and 
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viruses are known not to activate MAIT cells (238). Therefore, 
the above findings are consistent with the hypothesis that the 
observed numerical change in the MAIT cell compartment of 
septic patients is dictated by the type of pathogen(s) encountered. 
Second, Grimaldi et al. found a higher cumulative incidence of 
ICU-acquired infections in patients with a persistent decline 
in peripheral blood MAIT cells. In fact, patients who did not 
develop secondary infections showed a gradual return to normal 
MAIT cell values. Therefore, sepsis-induced changes in the MAIT 
cell compartment seem to be reversible by nature.
It is not clear why MAIT cell numbers drop early in sepsis. 
Apoptotic cell death, TCR internalization, and migration to 
peripheral tissues, for instance toward the infectious focus/foci, 
may provide an explanation for this phenomenon. The latter 
possibility is supported by the observation that in a few patients 
registered in the above study, a higher proportion of MAIT cells 
was detectable in unspecified biological fluids than in blood (238). 
This is reminiscent of previous reports that MAIT cell numbers 
drop in the peripheral blood but increase in the lungs of patients 
with tuberculosis (238, 239). Monitoring MAIT cell frequencies 
in individual septic patients and future mechanistic studies to 
uncover the cause of MAIT cell decline in the blood circulation 
will be informative.
Outstanding Questions and Concluding 
Remarks
Despite decades of active research and numerous clinical tri-
als, sepsis continues to take its Toll on human lives and cause 
significant morbidity, thus imposing a heavy burden on human 
populations and healthcare systems worldwide. Standardized 
management protocols and better ICU facilities have improved 
sepsis outcomes. However, there is currently no “cure” for this 
devastating syndrome. Targeting conventional T cells, APCs or 
individual inflammatory cytokines has not met with success. We 
propose that NKT and MAIT cells provide attractive targets for 
immunotherapy of sepsis. This is because: (i) they are abundant 
in certain anatomic locations where microbial pathogens are first 
encountered. For instance, iNKT cells are enriched in the human 
omentum (16), for which the term “policeman of the abdomen” 
was coined by a British surgeon, Rutherford Morison, in 1906 
(240). Human MAIT cells may serve as “gate-keepers” in mucosal 
layers and within the liver where they are highly abundant (66); 
(ii) NKT and MAIT cells can be activated early in the course of 
sepsis; (iii) they produce large quantities of immunomodulatory 
cytokines that control the function of downstream innate and 
adaptive effector cells, thus setting the tone for subsequent host 
responses; (iv) NKT and MAIT cells are restricted by monomor-
phic Ag-presenting molecules (i.e., CD1d and MR1, respectively) 
as opposed to distinct HLA allomorphs. Therefore, they can be 
stimulated and potentially manipulated by universal ligands in 
many, if not most, septic patients. This saves time and allows for 
therapeutic interventions to be implemented speedily; (v) using 
Th1- or Th2-polarizing ligands, typically in the case of iNKT cells, 
provides flexibility in tailoring therapies to sepsis stages in which 
hyper- or hypoinflammatory responses predominate.
Evolutionary conservation of CD1d and MR1 recognition 
across mammalian species makes animal models of sepsis par-
ticularly useful for studying NKT and MAIT cells. There is an 
urgent need for more investigations in models that mirror aging 
and various co-morbidities. Humanized mouse models should 
also shed mechanistic light on how clinical sepsis is initiated, 
perpetuated, or regulated. Such models could also potentially 
address some of the discrepancies noted between the results of 
rodent and human studies on NKT/MAIT cell frequencies, effec-
tor functions and homing properties.
Currently available Jα18−/− mice that have been used exten-
sively by many investigators including us were recently found 
to lack T cells other than iNKT cells (213). Therefore, if based 
merely on Jα18−/− mice, the findings of preclinical studies on 
sepsis need to be revisited. Antibody-mediated depletion of NKT 
and NK cells in parallel (45, 221) and functional inactivation 
of iNKT cells by carefully timed α-GalCer treatment (226) are 
among other experimental options to study these cells in  vivo. 
Using Jα18−/− and CD1d−/− mice reconstituted with iNKT cells 
should help solidify our knowledge of the roles that these cells 
play in sepsis. Reconstitution with CD4+ or double-negative 
subsets or with iNKT cells isolated from different tissues will 
enable functional studies on these cells in the context of sepsis. 
This is particularly important in light of reported functional 
differences between various iNKT cell subpopulations in other 
conditions, such as cancer (17). Even if/when mouse models of 
iNKT cell deficiency allow for relatively convincing conclusions 
to be drawn, one has to remain cognizant of the possibility that 
iNKT cells may behave differently in their steady and activated 
states (241). Much remains to be learned about direct activation 
of iNKT cells by microbial glycolipids and SAgs likely secreted 
during polymicrobial sepsis. Future studies should also explore 
the therapeutic potentials of iNKT cell glycolipid agonists when 
used in combination with antibiotics.
There is a paucity of information on the role of vNKT cells in 
sepsis. This is due, at least largely, to a lack of powerful or stable 
experimental tools to study these cells. CD1d−/− mice are devoid 
of both vNKT and iNKT cells (50). Once exclusively iNKT cell-
deficient mice become available, they can be used in parallel with 
CD1d−/− animals to address the relative contribution of iNKT 
and vNKT cells to the septic response. Sulfatide-loaded CD1d 
tetramer reagents invented by Vipin Kumar’s laboratory provide 
a very useful tool for detection of vNKT cells (46) but are not very 
stable. Treatment with native sulfatide has been used as a means 
of vNKT cell activation in vivo. However, it is likely that sulfatide 
exerts other effects and engages other cell types in the body. 
Sulfatide-reactive, CD1d-restricted γδ T cells have been described 
in human (242, 243), but their presence in mice is not completely 
clear. Future studies will need to test the effect of other vNKT 
cell ligands on sepsis. One such ligand is lysophosphatidylcholine 
whose levels are in fact altered during inflammatory processes 
(244). Finally, vNKT and iNKT cells are known to cross-regulate 
each other in tumor models (245). Whether a similar cross-talk 
exists during sepsis remains an open question.
Exploration of MAIT cell roles in sepsis is still in its infancy. 
Mouse and human MAIT cells have distinct tissue distribution 
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and frequencies. However, inducing sepsis in MAIT cell-defi-
cient MR1−/− mice may still provide useful clues toward under-
standing the role of these cells in sepsis. In addition, mouse and 
human MR1 tetramer reagents (68), once more widely available, 
will undoubtedly advance the field of MAIT cell immunology. 
They will enable mechanistic and functional studies on MAIT 
cells and elucidate their effector and/or regulatory functions 
during sepsis.
CD1d- and MR1-restricted T cells have become a focus of 
intense investigation in recent years. The advent of novel and reli-
able tools, techniques and models by which to study these cells will 
better our understanding of their basic biology and therapeutic 
potentials in various disorders including sepsis. We remain 
optimistic that the remarkable, quick-acting and wide-ranging 
immunomodulatory functions of these cells can be harnessed to 
invent efficacious treatments for different stages of sepsis.
Acknowledgments
This work was supported by a Canadian Institutes of Health 
Research (CIHR) operating grant (MOP-130465) to S.M. Mansour 
Haeryfar. We thank members of the Haeryfar laboratory for 
helpful discussions. We apologize to investigators whose relevant 
work was not cited due to space limitations.
References
 1. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. 
Immunity (2014) 40(4):463–75. doi:10.1016/j.immuni.2014.04.001 
 2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 
(2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711 
 3. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat 
Immunol (2010) 11(3):197–206. doi:10.1038/ni.1841 
 4. Bendelac A. Positive selection of mouse NK1+ T cells by CD1-expressing 
cortical thymocytes. J Exp Med (1995) 182(6):2091–6. doi:10.1084/
jem.182.6.2091 
 5. Smiley ST, Kaplan MH, Grusby MJ. Immunoglobulin E production in the 
absence of interleukin-4-secreting CD1-dependent cells. Science (1997) 
275(5302):977–9. doi:10.1126/science.275.5302.977 
 6. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. 
CD1d-mediated recognition of an alpha-galactosylceramide by natural killer 
T cells is highly conserved through mammalian evolution. J Exp Med (1998) 
188(8):1521–8. doi:10.1084/jem.188.8.1521 
 7. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol 
(2006) 177(2):769–75. doi:10.4049/jimmunol.177.2.769 
 8. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting 
cells. Curr Top Microbiol Immunol (2007) 314:113–41. 
 9. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification 
of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp 
Med (2000) 191(11):1895–903. doi:10.1084/jem.191.11.1895 
 10. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, 
et al. Tracking the response of natural killer T cells to a glycolipid antigen 
using CD1d tetramers. J Exp Med (2000) 192(5):741–54. doi:10.1084/
jem.192.5.741 
 11. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, Wong CH, et al. Structural 
basis for CD1d presentation of a sulfatide derived from myelin and its impli-
cations for autoimmunity. J Exp Med (2005) 202(11):1517–26. doi:10.1084/
jem.20051625 
 12. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT 
cells: what’s in a name? Nat Rev Immunol (2004) 4(3):231–7. doi:10.1038/
nri1309 
 13. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, et al. Cutting 
edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-ga-
lactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol (2002) 
168(7):3140–4. doi:10.4049/jimmunol.168.7.3140 
 14. Park SH, Benlagha K, Lee D, Balish E, Bendelac A. Unaltered 
phenotype, tissue distribution and function of Valpha14(+) 
NKT cells in germ-free mice. Eur J Immunol (2000) 30(2):620–5. 
doi:10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.3.CO;2-W 
 15. D’Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta 
A, et  al. Neonatal invariant Valpha24+ NKT lymphocytes are 
activated memory cells. Eur J Immunol (2000) 30(6):1544–50. 
doi:10.1002/1521-4141(200006)30:6<1544::AID-IMMU1544>3.0.CO;2-I 
 16. Lynch L, O’Shea D, Winter DC, Geoghegan J, Doherty DG, O’Farrelly C. 
Invariant NKT cells and CD1d(+) cells amass in human omentum and 
are depleted in patients with cancer and obesity. Eur J Immunol (2009) 
39(7):1893–901. doi:10.1002/eji.200939349 
 17. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of 
human V(alpha)24 natural killer T cells. J Exp Med (2002) 195(5):637–41. 
doi:10.1084/jem.20011908 
 18. Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, Lester C, et  al. 
Regulatory iNKT cells lack expression of the transcription factor PLZF and 
control the homeostasis of T(reg) cells and macrophages in adipose tissue. 
Nat Immunol (2015) 16(1):85–95. doi:10.1038/ni.3047 
 19. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The 
BTB-zinc finger transcriptional regulator PLZF controls the development 
of invariant natural killer T cell effector functions. Nat Immunol (2008) 
9(9):1055–64. doi:10.1038/ni.1641 
 20. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like 
nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 
NKT cells. Proc Natl Acad Sci U S A (1998) 95(10):5690–3. doi:10.1073/
pnas.95.10.5690 
 21. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. TRAIL 
expression by activated human CD4(+)V alpha 24NKT cells induces in vitro 
and in vivo apoptosis of human acute myeloid leukemia cells. Blood (2001) 
97(7):2067–74. doi:10.1182/blood.V97.7.2067 
 22. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d 
by myelomonocytic leukemias provides a target for cytotoxic NKT cells. 
Leukemia (2003) 17(6):1068–77. doi:10.1038/sj.leu.2402943 
 23. Kim HS, Chung DH. IL-9-producing invariant NKT cells protect against 
DSS-induced colitis in an IL-4-dependent manner. Mucosal Immunol (2013) 
6(2):347–57. doi:10.1038/mi.2012.77 
 24. Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10-producing 
NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest 
(2014) 124(9):3725–40. doi:10.1172/JCI72308 
 25. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, et  al. 
Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised 
for rapid effector function. J Exp Med (2003) 198(7):1069–76. doi:10.1084/
jem.20030630 
 26. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C III, Zhou D, et al. Exogenous 
and endogenous glycolipid antigens activate NKT cells during microbial 
infections. Nature (2005) 434(7032):525–9. doi:10.1038/nature03408 
 27. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells 
in the response to microorganisms. Nat Rev Microbiol (2007) 5(6):405–17. 
doi:10.1038/nrmicro1657 
 28. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural 
killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. 
Nat Immunol (2011) 12(10):966–74. doi:10.1038/ni.2096 
 29. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SM. NKT cell costimula-
tion: experimental progress and therapeutic promise. Trends Mol Med (2011) 
17(2):65–77. doi:10.1016/j.molmed.2010.10.007 
 30. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et  al. 
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells 
by glycosylceramides. Science (1997) 278(5343):1626–9. doi:10.1126/
science.278.5343.1626 
 31. Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, et  al. The 
identification of the endogenous ligands of natural killer T cells reveals the 
presence of mammalian alpha-linked glycosylceramides. Immunity (2014) 
41(4):543–54. doi:10.1016/j.immuni.2014.08.017 
August 2015 | Volume 6 | Article 40118
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
 32. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, et  al. 
CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. 
Nature (2007) 448(7149):44–9. doi:10.1038/nature05907 
 33. McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, et al. 
The length of lipids bound to human CD1d molecules modulates the affinity 
of NKT cell TCR and the threshold of NKT cell activation. J Exp Med (2007) 
204(5):1131–44. doi:10.1084/jem.20062342 
 34. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoim-
mune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 
(2001) 413(6855):531–4. doi:10.1038/35097097 
 35. Haeryfar SM, Lan Z, Leon-Ponte M, Duffy KR, Ge W, Liu W, et  al. 
Prolongation of cardiac allograft survival by rapamycin and the invariant nat-
ural killer T cell glycolipid agonist OCH. Transplantation (2008) 86(3):460–8. 
doi:10.1097/TP.0b013e3181806b72 
 36. Walker KM, Rytelewski M, Mazzuca DM, Meilleur SA, Mannik LA, Yue D, 
et  al. Preventing and curing citrulline-induced autoimmune arthritis in a 
humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol 
Cell Biol (2012) 90(6):630–9. doi:10.1038/icb.2011.78 
 37. Anantha RV, Mazzuca DM, Xu SX, Porcelli SA, Fraser DD, Martin CM, et al. T 
helper type 2-polarized invariant natural killer T cells reduce disease severity 
in acute intra-abdominal sepsis. Clin Exp Immunol (2014) 178(2):292–309. 
doi:10.1111/cei.12404 
 38. Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES, et al. Improved out-
comes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell acti-
vator. J Immunol (2007) 178(3):1415–25. doi:10.4049/jimmunol.178.3.1415 
 39. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, et al. Glycolipid 
alpha-C-galactosylceramide is a distinct inducer of dendritic cell function 
during innate and adaptive immune responses of mice. Proc Natl Acad Sci U 
S A (2006) 103(30):11252–7. doi:10.1073/pnas.0604812103 
 40. Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, et  al. 
Kinetics and cellular site of glycolipid loading control the outcome of nat-
ural killer T cell activation. Immunity (2009) 30(6):888–98. doi:10.1016/j.
immuni.2009.03.022 
 41. Bai L, Constantinides MG, Thomas SY, Reboulet R, Meng F, Koentgen 
F, et  al. Distinct APCs explain the cytokine bias of alpha-galactosylcer-
amide variants in  vivo. J Immunol (2012) 188(7):3053–61. doi:10.4049/
jimmunol.1102414 
 42. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Both CD1d antigen 
presentation and interleukin-12 are required to activate natural killer T cells 
during Trypanosoma cruzi infection. Infect Immun (2005) 73(3):1890–4. 
doi:10.1128/IAI.73.3.1890-1894.2005 
 43. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant 
NKT cells recognize Mycobacterium tuberculosis-infected macrophages, pro-
duce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 
4(12):e1000239. doi:10.1371/journal.ppat.1000239 
 44. Leite-De-Moraes MC, Hameg A, Arnould A, Machavoine F, Koezuka Y, 
Schneider E, et  al. A distinct IL-18-induced pathway to fully activate NK 
T lymphocytes independently from TCR engagement. J Immunol (1999) 
163(11):5871–6. 
 45. Hayworth JL, Mazzuca DM, Maleki Vareki S, Welch I, McCormick JK, 
Haeryfar SM. CD1d-independent activation of mouse and human iNKT 
cells by bacterial superantigens. Immunol Cell Biol (2012) 90(7):699–709. 
doi:10.1038/icb.2011.90 
 46. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention 
of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T 
cell population reactive to sulfatide. J Exp Med (2004) 199(7):947–57. 
doi:10.1084/jem.20031389 
 47. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II 
natural killer T lymphocytes in health and disease. Scand J Immunol (2012) 
76(3):246–55. doi:10.1111/j.1365-3083.2012.02750.x 
 48. Girardi E, Maricic I, Wang J, Mac TT, Iyer P, Kumar V, et al. Type II natural 
killer T cells use features of both innate-like and conventional T cells to rec-
ognize sulfatide self antigens. Nat Immunol (2012) 13(9):851–6. doi:10.1038/
ni.2371 
 49. Zhao J, Weng X, Bagchi S, Wang CR. Polyclonal type II natural killer T 
cells require PLZF and SAP for their development and contribute to CpG-
mediated antitumor response. Proc Natl Acad Sci U S A (2014) 111(7):2674–9. 
doi:10.1073/pnas.1323845111 
 50. Forestier C, Park SH, Wei D, Benlagha K, Teyton L, Bendelac A. T cell develop-
ment in mice expressing CD1d directed by a classical MHC class II promoter. 
J Immunol (2003) 171(8):4096–104. doi:10.4049/jimmunol.171.8.4096 
 51. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets 
define a new immunoregulatory axis. J Immunol (2008) 180(6):3627–35. 
doi:10.4049/jimmunol.180.6.3627 
 52. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory 
and anti-inflammatory functions of different subsets of CD1d-restricted nat-
ural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 
73(1):181–92. doi:10.1128/IAI.73.1.181-192.2005 
 53. Mallevaey T, Zanetta JP, Faveeuw C, Fontaine J, Maes E, Platt F, et  al. 
Activation of invariant NKT cells by the helminth parasite Schistosoma man-
soni. J Immunol (2006) 176(4):2476–85. doi:10.4049/jimmunol.176.4.2476 
 54. Gold MC, Lewinsohn DM. Co-dependents: MR1-restricted MAIT cells 
and their antimicrobial function. Nat Rev Microbiol (2013) 11(1):14–9. 
doi:10.1038/nrmicro2918 
 55. Gapin L. Check MAIT. J Immunol (2014) 192(10):4475–80. doi:10.4049/
jimmunol.1400119 
 56. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et  al. 
An invariant T cell receptor alpha chain defines a novel TAP-independent 
major histocompatibility complex class Ib-restricted alpha/beta T cell sub-
population in mammals. J Exp Med (1999) 189(12):1907–21. doi:10.1084/
jem.189.12.1907 
 57. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen recep-
tor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells 
demonstrates preferential use of several V beta genes and an invariant TCR 
alpha chain. J Exp Med (1993) 178(1):1–16. doi:10.1084/jem.178.1.1 
 58. Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, et al. Double-
positive thymocytes select mucosal-associated invariant T cells. J Immunol 
(2013) 191(12):6002–9. doi:10.4049/jimmunol.1301212 
 59. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. 
Selection of evolutionarily conserved mucosal-associated invariant T cells by 
MR1. Nature (2003) 422(6928):164–9. doi:10.1038/nature01433 
 60. Riegert P, Wanner V, Bahram S. Genomics, isoforms, expression, and phylog-
eny of the MHC class I-related MR1 gene. J Immunol (1998) 161(8):4066–77. 
 61. Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, et al. MR1 antigen 
presentation to mucosal-associated invariant T cells was highly conserved 
in evolution. Proc Natl Acad Sci U S A (2009) 106(20):8290–5. doi:10.1073/
pnas.0903196106 
 62. Tsukamoto K, Deakin JE, Graves JA, Hashimoto K. Exceptionally high 
conservation of the MHC class I-related gene, MR1, among mammals. 
Immunogenetics (2013) 65(2):115–24. doi:10.1007/s00251-012-0666-5 
 63. Leeansyah E, Loh L, Nixon DF, Sandberg JK. Acquisition of innate-like 
microbial reactivity in mucosal tissues during human fetal MAIT-cell devel-
opment. Nat Commun (2014) 5:3143. doi:10.1038/ncomms4143 
 64. Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, 
Fleming VM, et al. Human MAIT and CD8alphaalpha cells develop from 
a pool of type-17 precommitted CD8+ T cells. Blood (2012) 119(2):422–33. 
doi:10.1182/blood-2011-05-353789 
 65. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human 
MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting 
T cells. Blood (2011) 117(4):1250–9. doi:10.1182/blood-2010-08-303339 
 66. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et  al. IL-7 licenses 
activation of human liver intrasinusoidal mucosal-associated invariant T 
cells. J Immunol (2013) 190(7):3142–52. doi:10.4049/jimmunol.1203218 
 67. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et  al. Stepwise 
development of MAIT cells in mouse and human. PLoS Biol (2009) 7(3):e54. 
doi:10.1371/journal.pbio.1000054 
 68. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, 
et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in 
mucosal-associated invariant T cells. J Exp Med (2013) 210(11):2305–20. 
doi:10.1084/jem.20130958 
 69. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for 
optimal mucosal immune responses during in  vivo pulmonary bacterial 
infection. Proc Natl Acad Sci U S A (2013) 110(33):E3119–28. doi:10.1073/
pnas.1302799110 
 70. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. 
MAIT cells are licensed through granzyme exchange to kill bacterially 
August 2015 | Volume 6 | Article 40119
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
sensitized targets. Mucosal Immunol (2015) 8(2):429–40. doi:10.1038/
mi.2014.81 
 71. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, et al. 
MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS 
Pathog (2013) 9(10):e1003681. doi:10.1371/journal.ppat.1003681 
 72. Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-con-
ventional MHC class I MR1 molecule controls infection by Klebsiella 
pneumoniae in mice. Mol Immunol (2011) 48(5):769–75. doi:10.1016/j.
molimm.2010.12.002 
 73. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. 
Polyclonal mucosa-associated invariant T cells have unique innate functions 
in bacterial infection. Infect Immun (2012) 80(9):3256–67. doi:10.1128/
IAI.00279-12 
 74. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 
presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 
491(7426):717–23. doi:10.1038/nature11605 
 75. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell 
activation by transitory neo-antigens derived from distinct microbial path-
ways. Nature (2014) 509(7500):361–5. doi:10.1038/nature13160 
 76. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, et al. 
In vitro and in vivo analysis of the Gram-negative bacteria-derived ribofla-
vin precursor derivatives activating mouse MAIT cells. J Immunol (2015) 
194(10):4641–9. doi:10.4049/jimmunol.1403224 
 77. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. 
CD161++ CD8+ T cells, including the MAIT cell subset, are specifically 
activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol 
(2014) 44(1):195–203. doi:10.1002/eji.201343509 
 78. Majno G. The ancient riddle of sigma eta psi iota sigma (sepsis). J Infect Dis 
(1991) 163(5):937–45. doi:10.1093/infdis/163.5.937 
 79. MacFie J. Surgical sepsis. Br J Surg (2013) 100(9):1119–22. doi:10.1002/
bjs.9155_1 
 80. Cerra FB. The systemic septic response: multiple systems organ failure. Crit 
Care Clin (1985) 1(3):591–607. 
 81. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et  al. 
Definitions for sepsis and organ failure and guidelines for the use of innova-
tive therapies in sepsis. The ACCP/SCCM consensus conference committee. 
American college of chest physicians/society of critical care medicine. Chest 
(1992) 101(6):1644–55. doi:10.1378/chest.101.6.1644 
 82. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky 
MR. Epidemiology of severe sepsis in the United States: analysis of incidence, 
outcome, and associated costs of care. Crit Care Med (2001) 29(7):1303–10. 
doi:10.1097/00003246-200107000-00002 
 83. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 
(2014) 5(1):4–11. doi:10.4161/viru.27372 
 84. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impair-
ment and functional disability among survivors of severe sepsis. JAMA 
(2010) 304(16):1787–94. doi:10.1001/jama.2010.1553 
 85. Shapiro NI, Howell MD, Talmor D, Donnino M, Ngo L, Bates DW. Mortality 
in emergency department sepsis (MEDS) score predicts 1-year mortality. Crit 
Care Med (2007) 35(1):192–8. doi:10.1097/01.CCM.0000251508.12555.3E 
 86. Martin GS, Mannino DM, Moss M. The effect of age on the development and 
outcome of adult sepsis. Crit Care Med (2006) 34(1):15–21. doi:10.1097/01.
CCM.0000194535.82812.BA 
 87. Yang Y, Yang KS, Hsann YM, Lim V, Ong BC. The effect of comorbidity and 
age on hospital mortality and length of stay in patients with sepsis. J Crit Care 
(2010) 25(3):398–405. doi:10.1016/j.jcrc.2009.09.001 
 88. Nasa P, Juneja D, Singh O, Dang R, Arora V. Severe sepsis and its impact on 
outcome in elderly and very elderly patients admitted in intensive care unit. 
J Intensive Care Med (2012) 27(3):179–83. doi:10.1177/0885066610397116 
 89. Nasa P, Juneja D, Singh O. Severe sepsis and septic shock in the elderly: an 
overview. World J Crit Care Med (2012) 1(1):23–30. doi:10.5492/wjccm.
v1.i1.23 
 90. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving sepsis campaign: international guidelines for management of 
severe sepsis and septic shock: 2012. Crit Care Med (2013) 41(2):580–637. 
doi:10.1097/CCM.0b013e31827e83af 
 91. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med (2013) 
369(9):840–51. doi:10.1056/NEJMra1208623 
 92. Gu WJ, Wang F, Bakker J, Tang L, Liu JC. The effect of goal-directed therapy 
on mortality in patients with sepsis  –  earlier is better: a meta-analysis of 
randomized controlled trials. Crit Care (2014) 18(5):570. doi:10.1186/
s13054-014-0570-5 
 93. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect 
Dis (2008) 8(1):32–43. doi:10.1016/S1473-3099(07)70265-7 
 94. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. 
Shock and tissue injury induced by recombinant human cachectin. Science 
(1986) 234(4775):470–4. doi:10.1126/science.3764421 
 95. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-
cachectin/TNF monoclonal antibodies prevent septic shock during lethal 
bacteraemia. Nature (1987) 330(6149):662–4. doi:10.1038/330662a0 
 96. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton 
JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and 
tumor necrosis factor-alpha. J Immunol (1992) 149(5):1666–70. 
 97. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cyto-
kine levels in human septic shock. Relation to multiple-system organ failure 
and mortality. Chest (1993) 103(2):565–75. doi:10.1378/chest.103.2.565 
 98. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et  al. 
Interleukin-3 amplifies acute inflammation and is a potential therapeutic 
target in sepsis. Science (2015) 347(6227):1260–5. doi:10.1126/science.
aaa4268 
 99. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel 
understanding of the disorder and a new therapeutic approach. Lancet Infect 
Dis (2013) 13(3):260–8. doi:10.1016/S1473-3099(13)70001-X 
 100. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, et al. The late 
phase of sepsis is characterized by an increased microbiological burden and 
death rate. Crit Care (2011) 15(4):R183. doi:10.1186/cc10332 
 101. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, 
et  al. Macroscopic postmortem findings in 235 surgical intensive care 
patients with sepsis. Anesth Analg (2009) 108(6):1841–7. doi:10.1213/
ane.0b013e318195e11d 
 102. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, 
et  al. Delayed hypersensitivity: indicator of acquired failure of host 
defenses in sepsis and trauma. Ann Surg (1977) 186(3):241–50. 
doi:10.1097/00000658-197709000-00002 
 103. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, et al. 
Reactivation of multiple viruses in patients with sepsis. PLoS One (2014) 
9(2):e98819. doi:10.1371/journal.pone.0098819 
 104. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. 
Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 
(1998) 351(9107):950–3. doi:10.1016/S0140-6736(05)60606-X 
 105. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-in-
flammatory cytokine profile in patients with severe sepsis: a marker for 
prognosis and future therapeutic options. J Infect Dis (2000) 181(1):176–80. 
doi:10.1086/315214 
 106. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, et  al. 
Downregulation of proinflammatory cytokine release in whole blood from 
septic patients. Blood (1995) 85(5):1341–7. 
 107. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation 
of in  vitro cytokine production by monocytes during sepsis. J Clin Invest 
(1991) 88(5):1747–54. doi:10.1172/JCI115493 
 108. Lopez-Collazo E, del Fresno C. Pathophysiology of endotoxin tolerance: 
mechanisms and clinical consequences. Crit Care (2013) 17(6):242. 
doi:10.1186/cc13110 
 109. Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, et al. 
Downregulation of CD40 ligand response in monocytes from sepsis patients. 
Clin Vaccine Immunol (2008) 15(12):1851–8. doi:10.1128/CVI.00184-08 
 110. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et  al. 
Immunosuppression in patients who die of sepsis and multiple organ failure. 
JAMA (2011) 306(23):2594–605. doi:10.1001/jama.2011.1829 
 111. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. 
Granulocyte-macrophage colony-stimulating factor to reverse sepsis-as-
sociated immunosuppression: a double-blind, randomized, placebo-con-
trolled multicenter trial. Am J Respir Crit Care Med (2009) 180(7):640–8. 
doi:10.1164/rccm.200903-0363OC 
 112. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, et  al. 
Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) 
August 2015 | Volume 6 | Article 40120
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 
(2009) 35(4):678–86. doi:10.1007/s00134-008-1337-8 
 113. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia 
KM, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) 
population induces T cell suppression and Th2 polarization in sepsis. J Exp 
Med (2007) 204(6):1463–74. doi:10.1084/jem.20062602 
 114. Shrum B, Anantha RV, Xu SX, Donnelly M, Haeryfar SM, McCormick JK, 
et al. A robust scoring system to evaluate sepsis severity in an animal model. 
BMC Res Notes (2014) 7:233. doi:10.1186/1756-0500-7-233 
 115. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, 
et al. Sepsis-induced apoptosis causes progressive profound depletion of B 
and CD4+ T lymphocytes in humans. J Immunol (2001) 166(11):6952–63. 
doi:10.4049/jimmunol.166.11.6952 
 116. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, 
Wagner TH, et  al. Depletion of dendritic cells, but not macrophages, in 
patients with sepsis. J Immunol (2002) 168(5):2493–500. doi:10.4049/
jimmunol.168.5.2493 
 117. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, 
lymphoid depletion, and hypoprolactinemia in children with nosocomial 
sepsis and multiple organ failure. J Immunol (2005) 174(6):3765–72. 
doi:10.4049/jimmunol.174.6.3765 
 118. Toti P, De Felice C, Occhini R, Schuerfeld K, Stumpo M, Epistolato MC, et al. 
Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 
(2004) 122(5):765–71. doi:10.1309/RV6E-9BMC-9954-A2WU 
 119. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. 
Immunosuppressive effects of apoptotic cells. Nature (1997) 390(6658):350–
1. doi:10.1038/37022 
 120. Faivre V, Lukaszewicz AC, Alves A, Charron D, Payen D, Haziot A. Human 
monocytes differentiate into dendritic cells subsets that induce anergic and 
regulatory T cells in sepsis. PLoS One (2012) 7(10):e47209. doi:10.1371/
journal.pone.0047209 
 121. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, 
et  al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and 
improves survival in sepsis. J Immunol (1999) 162(7):4148–56. 
 122. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman 
TG, et al. Prevention of lymphocyte cell death in sepsis improves survival 
in mice. Proc Natl Acad Sci U S A (1999) 96(25):14541–6. doi:10.1073/
pnas.96.25.14541 
 123. Donovan S, Bearman GM. Use of intravenous immunoglobulin in 
critically ill patients. Curr Infect Dis Rep (2014) 16(12):447. doi:10.1007/
s11908-014-0447-4 
 124. Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of 
HA-1A, a human monoclonal antibody to endotoxin, in children with 
meningococcal septic shock. European pediatric meningococcal septic shock 
trial study group. Clin Infect Dis (1999) 28(4):770–7. doi:10.1086/515184 
 125. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect 
of eritoran, an antagonist of MD2-TLR4, on mortality in patients with 
severe sepsis: the ACCESS randomized trial. JAMA (2013) 309(11):1154–62. 
doi:10.1001/jama.2013.2194 
 126. Rondon E, Venkataraman R. Afelimomab led to a modest mortality benefit in 
patients with severe sepsis and elevated interleukin-6 levels. Crit Care (2005) 
9(5):E20. doi:10.1186/cc3798 
 127. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, et al. 
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe 
sepsis and early septic shock: a randomized, double-blind, placebo-con-
trolled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 
29(3):503–10. doi:10.1097/00003246-200103000-00006 
 128. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et  al. 
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase 
III, randomized, double-blind, placebo-controlled, multicenter trial. The 
interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med 
(1997) 25(7):1115–24. doi:10.1097/00003246-199707000-00010 
 129. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, 
Permpikul C, et al. A double-blind placebo-controlled study of an infusion 
of lexipafant (platelet-activating factor receptor antagonist) in patients with 
severe sepsis. Antimicrob Agents Chemother (2000) 44(3):693–6. doi:10.1128/
AAC.44.3.693-696.2000 
 130. Bruno JJ, Dee BM, Anderegg BA, Hernandez M, Pravinkumar SE. US 
practitioner opinions and prescribing practices regarding corticosteroid 
therapy for severe sepsis and septic shock. J Crit Care (2012) 27(4):351–61. 
doi:10.1016/j.jcrc.2011.12.011 
 131. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et  al. 
Monocyte deactivation in septic patients: restoration by IFN-gamma treat-
ment. Nat Med (1997) 3(6):678–81. doi:10.1038/nm0697-678 
 132. Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R. Immune 
effects of interferon gamma in persistent staphylococcal sepsis. Am J Respir 
Crit Care Med (2012) 185(1):110–2. doi:10.1164/ajrccm.185.1.110 
 133. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. 
Immunoparalysis and nosocomial infection in children with multiple organ 
dysfunction syndrome. Intensive Care Med (2011) 37(3):525–32. doi:10.1007/
s00134-010-2088-x 
 134. Sprent J, Surh CD. Interleukin 7, maestro of the immune system. Semin 
Immunol (2012) 24(3):149–50. doi:10.1016/j.smim.2012.04.011 
 135. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. 
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells 
but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 
29(3):313–9. doi:10.1097/01.cji.0000210386.55951.c2 
 136. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, et  al. 
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J 
Clin Invest (2009) 119(4):997–1007. doi:10.1172/JCI38052 
 137. Alstadhaug KB, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch HH, 
et al. Treatment of progressive multifocal leukoencephalopathy with interleu-
kin 7. JAMA Neurol (2014) 71(8):1030–5. doi:10.1001/jamaneurol.2014.825 
 138. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, et al. Effects 
of recombinant human interleukin 7 on T-cell recovery and thymic output 
in HIV-infected patients receiving antiretroviral therapy: results of a phase I/
IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis (2012) 
55(2):291–300. doi:10.1093/cid/cis383 
 139. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et  al. 
Administration of rhIL-7 in humans increases in  vivo TCR repertoire 
diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 
205(7):1701–14. doi:10.1084/jem.20071681 
 140. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer 
JT, et  al. IL-7 promotes T cell viability, trafficking, and functionality and 
improves survival in sepsis. J Immunol (2010) 184(7):3768–79. doi:10.4049/
jimmunol.0903151 
 141. Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell 
CC, et  al. Interleukin-7 ameliorates immune dysfunction and improves 
survival in a 2-hit model of fungal sepsis. J Infect Dis (2012) 206(4):606–16. 
doi:10.1093/infdis/jis383 
 142. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, 
et al. IL-7 restores lymphocyte functions in septic patients. J Immunol (2012) 
189(10):5073–81. doi:10.4049/jimmunol.1202062 
 143. Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP. Sustained and 
incomplete recovery of naive CD8+ T cell precursors after sepsis contrib-
utes to impaired CD8+ T cell responses to infection. J Immunol (2013) 
190(5):1991–2000. doi:10.4049/jimmunol.1202379 
 144. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, et al. IL-
15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and 
improves survival in sepsis. J Immunol (2010) 184(3):1401–9. doi:10.4049/
jimmunol.0902307 
 145. Chung KP, Chang HT, Lo SC, Chang LY, Lin SY, Cheng A, et al. Severe lymph-
openia is associated with elevated plasma interleukin-15 levels and increased 
mortality during severe sepsis. Shock (2015) 43(6):569–75. doi:10.1097/
SHK.0000000000000347 
 146. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et  al. 
Restoring function in exhausted CD8 T cells during chronic viral infection. 
Nature (2006) 439(7077):682–7. doi:10.1038/nature04444 
 147. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. 
Delayed administration of anti-PD-1 antibody reverses immune dysfunction 
and improves survival during sepsis. J Leukoc Biol (2010) 88(2):233–40. 
doi:10.1189/jlb.0110037 
 148. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves 
survival in experimental sepsis by inhibiting lymphocyte apoptosis and 
August 2015 | Volume 6 | Article 40121
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
reversing monocyte dysfunction. Crit Care (2010) 14(6):R220. doi:10.1186/
cc9354 
 149. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation and 
the Host Response to Injury Investigators. Acute inflammatory response to 
endotoxin in mice and humans. Clin Diagn Lab Immunol (2005) 12(1):60–7. 
doi:10.1128/CDLI.12.1.60-67.2005 
 150. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the 
mortality and inflammatory response of two models of sepsis: lipopoly-
saccharide vs. cecal ligation and puncture. Shock (2000) 13(2):110–6. 
doi:10.1097/00024382-200013020-00004 
 151. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. 
Protective role of angiopoietin-1 in endotoxic shock. Circulation (2005) 
111(1):97–105. doi:10.1161/01.CIR.0000151287.08202.8E 
 152. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang 
EB. Glutamine reduces cytokine release, organ damage, and mor-
tality in a rat model of endotoxemia. Shock (2001) 16(5):398–402. 
doi:10.1097/00024382-200116050-00014 
 153. Lang CH, Bagby GJ, Spitzer JJ. Glucose kinetics and body temperature 
after lethal and nonlethal doses of endotoxin. Am J Physiol (1985) 248(4 Pt 
2):R471–8. 
 154. Taniguchi T, Shibata K, Yamamoto K, Mizukoshi Y, Kobayashi T. 
Effects of lidocaine administration on hemodynamics and cytokine 
responses to endotoxemia in rabbits. Crit Care Med (2000) 28(3):755–9. 
doi:10.1097/00003246-200004000-00032 
 155. Carvalho GL, Wakabayashi G, Shimazu M, Karahashi T, Yoshida M, 
Yamamoto S, et  al. Anti-interleukin-8 monoclonal antibody reduces 
free radical production and improves hemodynamics and survival rate 
in endotoxic shock in rabbits. Surgery (1997) 122(1):60–8. doi:10.1016/
S0039-6060(97)90265-8 
 156. Nielsen JS, Larsson A, Rix T, Nyboe R, Gjedsted J, Krog J, et al. The effect 
of activated protein C on plasma cytokine levels in a porcine model of 
acute endotoxemia. Intensive Care Med (2007) 33(6):1085–93. doi:10.1007/
s00134-007-0631-1 
 157. Jourdain M, Carrette O, Tournoys A, Fourrier F, Mizon C, Mangalaboyi J, 
et al. Effects of inter-alpha-inhibitor in experimental endotoxic shock and 
disseminated intravascular coagulation. Am J Respir Crit Care Med (1997) 
156(6):1825–33. doi:10.1164/ajrccm.156.6.9611100 
 158. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ. 
Antibodies against CD14 protect primates from endotoxin-induced shock. 
J Clin Invest (1996) 98(7):1533–8. doi:10.1172/JCI118945 
 159. Haudek SB, Natmessnig BE, Furst W, Bahrami S, Schlag G, Redl H. 
Lipopolysaccharide dose response in baboons. Shock (2003) 20(5):431–6. 
doi:10.1097/01.shk.0000090843.66556.74 
 160. Kreimeier U, Brueckner UB, Gerspach S, Veitinger K, Messmer K. A porcine 
model of hyperdynamic endotoxemia: pattern of respiratory, macrocircu-
latory, and regional blood flow changes. J Invest Surg (1993) 6(2):143–56. 
doi:10.3109/08941939309141605 
 161. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective 
LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 
Science (1998) 282(5396):2085–8. doi:10.1126/science.282.5396.2085 
 162. Fink MP. Animal models of sepsis. Virulence (2014) 5(1):143–53. doi:10.4161/
viru.26083 
 163. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models 
of sepsis and human sepsis. J Leukoc Biol (2007) 81(1):137–43. doi:10.1189/
jlb.0806542 
 164. Fink MP, Morrissey PE, Stein KL, Clement RE, Fiallo V, Gardiner WM. 
Systemic and regional hemodynamic effects of cyclo-oxygenase and throm-
boxane synthetase inhibition in normal and hyperdynamic endotoxemic 
rabbits. Circ Shock (1988) 26(1):41–57. 
 165. Xu D, Qi L, Guillory D, Cruz N, Berg R, Deitch EA. Mechanisms of endo-
toxin-induced intestinal injury in a hyperdynamic model of sepsis. J Trauma 
(1993) 34(5):676–82. doi:10.1097/00005373-199305000-00010 
 166. Breslow MJ, Miller CF, Parker SD, Walman AT, Traystman RJ. Effect of vaso-
pressors on organ blood flow during endotoxin shock in pigs. Am J Physiol 
(1987) 252(2 Pt 2):H291–300. 
 167. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the 
stage. Nat Rev Drug Discov (2005) 4(10):854–65. doi:10.1038/nrd1854 
 168. Billiau A. Gamma-interferon: the match that lights the fire? Immunol Today 
(1988) 9(2):37–40. doi:10.1016/0167-5699(88)91256-X 
 169. Morris M, Li L. Molecular mechanisms and pathological consequences of 
endotoxin tolerance and priming. Arch Immunol Ther Exp (Warsz) (2012) 
60(1):13–8. doi:10.1007/s00005-011-0155-9 
 170. Macarthur H, Couri DM, Wilken GH, Westfall TC, Lechner AJ, Matuschak 
GM, et  al. Modulation of serum cytokine levels by a novel superoxide 
dismutase mimetic, M40401, in an Escherichia coli model of septic shock: 
correlation with preserved circulating catecholamines. Crit Care Med (2003) 
31(1):237–45. doi:10.1097/01.CCM.0000045202.66538.DB 
 171. Pass LJ, Schloerb PR, Pearce FJ, Drucker WR. Cardiopulmonary response 
of the rat to Gram-negative bacteremia. Am J Physiol (1984) 246(3 Pt 
2):H344–50. 
 172. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A spe-
cific receptor antagonist for interleukin 1 prevents Escherichia coli-induced 
shock in rabbits. FASEB J (1991) 5(3):338–43. 
 173. Castellheim A, Thorgersen EB, Hellerud BC, Pharo A, Johansen HT, 
Brosstad F, et  al. New biomarkers in an acute model of live Escherichia 
coli-induced sepsis in pigs. Scand J Immunol (2008) 68(1):75–84. 
doi:10.1111/j.1365-3083.2008.02122.x 
 174. Kazarian KK, Perdue PW, Lynch W, Dziki A, Nevola J, Lee CH, et al. Porcine 
peritoneal sepsis: modeling for clinical relevance. Shock (1994) 1(3):201–12. 
doi:10.1097/00024382-199403000-00008 
 175. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, 
et al. Recombinant human antithrombin III improves survival and attenuates 
inflammatory responses in baboons lethally challenged with Escherichia coli. 
Blood (2000) 95(4):1117–23. 
 176. Carroll GC, Snyder JV. Hyperdynamic severe intravascular sepsis depends 
on fluid administration in cynomolgus monkey. Am J Physiol (1982) 
243(1):R131–41. 
 177. Cryer HM, Garrison RN, Kaebnick HW, Harris PD, Flint LM. Skeletal 
microcirculatory responses to hyperdynamic Escherichia coli sepsis 
in unanesthetized rats. Arch Surg (1987) 122(1):86–92. doi:10.1001/
archsurg.1987.01400130092014 
 178. Rimmele T, Assadi A, Benatir F, Boselli E, Kaminski C, Arnal F, et  al. 
Validation of a Pseudomonas aeruginosa porcine model of septic shock. J 
Infect (2006) 53(3):199–205. doi:10.1016/j.jinf.2005.10.023 
 179. Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models 
of sepsis. Infect Immun (1993) 61(7):2741–7. 
 180. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, et al. Cytokine 
production after intravenous or peritoneal Gram-negative bacterial challenge 
in mice. Comparative protective efficacy of antibodies to tumor necrosis 
factor-alpha and to lipopolysaccharide. J Immunol (1992) 148(6):1890–7. 
 181. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, et al. 
The duration of hypotension before the initiation of antibiotic treatment is a 
critical determinant of survival in a murine model of Escherichia coli septic 
shock: association with serum lactate and inflammatory cytokine levels. J 
Infect Dis (2006) 193(2):251–8. doi:10.1086/498909 
 182. Matute-Bello G, Frevert CW, Kajikawa O, Skerrett SJ, Goodman RB, Park DR, 
et al. Septic shock and acute lung injury in rabbits with peritonitis: failure of 
the neutrophil response to localized infection. Am J Respir Crit Care Med 
(2001) 163(1):234–43. doi:10.1164/ajrccm.163.1.9909034 
 183. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo 
JE. Gram-negative bacteremia produces both severe systolic and diastolic 
cardiac dysfunction in a canine model that simulates human septic shock. J 
Clin Invest (1986) 78(1):259–70. doi:10.1172/JCI112559 
 184. Goldfarb RD, Glock D, Kumar A, McCarthy RJ, Mei J, Guynn T, et  al. A 
porcine model of peritonitis and bacteremia simulates human septic shock. 
Shock (1996) 6(6):442–51. doi:10.1097/00024382-199612000-00009 
 185. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Feuerstein G, Rabinovici R. 
An improved clinically relevant sepsis model in the conscious rat. Crit Care 
Med (2000) 28(6):1947–52. doi:10.1097/00003246-200006000-00043 
 186. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of exper-
imental sepsis by cecal ligation and puncture. Nat Protoc (2009) 4(1):31–6. 
doi:10.1038/nprot.2008.214 
 187. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/
inhibitor profiles reshape the understanding of the SIRS/CARS continuum in 
August 2015 | Volume 6 | Article 40122
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
sepsis and predict mortality. J Immunol (2006) 177(3):1967–74. doi:10.4049/
jimmunol.177.3.1967 
 188. Hollenberg SM, Dumasius A, Easington C, Colilla SA, Neumann A, Parrillo 
JE. Characterization of a hyperdynamic murine model of resuscitated sepsis 
using echocardiography. Am J Respir Crit Care Med (2001) 164(5):891–5. 
doi:10.1164/ajrccm.164.5.2010073 
 189. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith 
CM, et  al. Characterization and modulation of the immunosuppressive 
phase of sepsis. Infect Immun (2010) 78(4):1582–92. doi:10.1128/
IAI.01213-09 
 190. Lustig MK, Bac VH, Pavlovic D, Maier S, Grundling M, Grisk O, et al. Colon 
ascendens stent peritonitis – a model of sepsis adopted to the rat: physio-
logical, microcirculatory and laboratory changes. Shock (2007) 28(1):59–64. 
doi:10.1097/SHK.0b013e31802e454f 
 191. Wang P, Ba ZF, Chaudry IH. Hepatic extraction of indocyanine green 
is depressed early in sepsis despite increased hepatic blood flow 
and cardiac output. Arch Surg (1991) 126(2):219–24. doi:10.1001/
archsurg.1991.01410260109015 
 192. Brooks HF, Osabutey CK, Moss RF, Andrews PL, Davies DC. Caecal 
ligation and puncture in the rat mimics the pathophysiological changes in 
human sepsis and causes multi-organ dysfunction. Metab Brain Dis (2007) 
22(3–4):353–73. doi:10.1007/s11011-007-9058-1 
 193. Muenzer JT, Davis CG, Dunne BS, Unsinger J, Dunne WM, Hotchkiss 
RS. Pneumonia after cecal ligation and puncture: a clinically relevant 
“two-hit” model of sepsis. Shock (2006) 26(6):565–70. doi:10.1097/01.
shk.0000235130.82363.ed 
 194. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, 
Sherwood ER. Diminished bacterial clearance is associated with decreased 
IL-12 and interferon-gamma production but a sustained proinflammatory 
response in a murine model of postseptic immunosuppression. Shock (2004) 
21(5):415–25. doi:10.1097/00024382-200405000-00004 
 195. Pene F, Zuber B, Courtine E, Rousseau C, Ouaaz F, Toubiana J, et al. Dendritic 
cells modulate lung response to Pseudomonas aeruginosa in a murine model 
of sepsis-induced immune dysfunction. J Immunol (2008) 181(12):8513–20. 
doi:10.4049/jimmunol.181.12.8513 
 196. Benjamim CF, Hogaboam CM, Lukacs NW, Kunkel SL. Septic mice are 
susceptible to pulmonary aspergillosis. Am J Pathol (2003) 163(6):2605–17. 
doi:10.1016/S0002-9440(10)63615-2 
 197. Singleton KD, Wischmeyer PE. Distance of cecum ligated influences mor-
tality, tumor necrosis factor-alpha and interleukin-6 expression following 
cecal ligation and puncture in the rat. Eur Surg Res (2003) 35(6):486–91. 
doi:10.1159/000073387 
 198. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. 
Immunopathologic alterations in murine models of sepsis of increasing 
severity. Infect Immun (1999) 67(12):6603–10. 
 199. Medina E. Murine model of polymicrobial septic peritonitis using 
cecal ligation and puncture (CLP). Methods Mol Biol (2010) 602:411–5. 
doi:10.1007/978-1-60761-058-8_23 
 200. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock – a review 
of laboratory models and a proposal. J Surg Res (1980) 29(2):189–201. 
doi:10.1016/0022-4804(80)90037-2 
 201. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, et  al. 
Cecal ligation and puncture versus colon ascendens stent peritonitis: two 
distinct animal models for polymicrobial sepsis. Shock (2004) 21(6):505–11. 
doi:10.1097/01.shk.0000126906.52367.dd 
 202. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, et  al. 
Essential role of gamma interferon in survival of colon ascendens stent 
peritonitis, a novel murine model of abdominal sepsis. Infect Immun (1998) 
66(5):2300–9. 
 203. Zolfaghari PS, Pinto BB, Dyson A, Singer M. The metabolic phenotype of 
rodent sepsis: cause for concern? Intensive Care Med Exp (2013) 1(1):6. 
doi:10.1186/2197-425X-1-6 
 204. Chvojka J, Sykora R, Krouzecky A, Radej J, Varnerova V, Karvunidis T, et al. 
Renal haemodynamic, microcirculatory, metabolic and histopathological 
responses to peritonitis-induced septic shock in pigs. Crit Care (2008) 
12(6):R164. doi:10.1186/cc7164 
 205. Correa TD, Vuda M, Blaser AR, Takala J, Djafarzadeh S, Dunser MW, et al. 
Effect of treatment delay on disease severity and need for resuscitation in 
porcine fecal peritonitis. Crit Care Med (2012) 40(10):2841–9. doi:10.1097/
CCM.0b013e31825b916b 
 206. Gentile LF, Nacionales DC, Lopez MC, Vanzant E, Cuenca A, Szpila BE, et al. 
Host responses to sepsis vary in different low-lethality murine models. PLoS 
One (2014) 9(5):e94404. doi:10.1371/journal.pone.0094404 
 207. Rhee RJ, Carlton S, Lomas JL, Lane C, Brossay L, Cioffi WG, et al. Inhibition 
of CD1d activation suppresses septic mortality: a role for NK-T cells in 
septic immune dysfunction. J Surg Res (2003) 115(1):74–81. doi:10.1016/
S0022-4804(03)00220-8 
 208. Teng MW, Yue S, Sharkey J, Exley MA, Smyth MJ. CD1d activation and 
blockade: a new antitumor strategy. J Immunol (2009) 182(6):3366–71. 
doi:10.4049/jimmunol.0802964 
 209. Dieude M, Striegl H, Tyznik AJ, Wang J, Behar SM, Piccirillo CA, et  al. 
Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T 
cells in the normal murine repertoire. J Immunol (2011) 186(8):4771–81. 
doi:10.4049/jimmunol.1000921 
 210. Hu CK, Venet F, Heffernan DS, Wang YL, Horner B, Huang X, et  al. The 
role of hepatic invariant NKT cells in systemic/local inflammation and mor-
tality during polymicrobial septic shock. J Immunol (2009) 182(4):2467–75. 
doi:10.4049/jimmunol.0801463 
 211. Kattan OM, Kasravi FB, Elford EL, Schell MT, Harris HW. Apolipoprotein 
E-mediated immune regulation in sepsis. J Immunol (2008) 181(2):1399–408. 
doi:10.4049/jimmunol.181.2.1399 
 212. Van Kaer L. Alpha-galactosylceramide therapy for autoimmune diseases: 
prospects and obstacles. Nat Rev Immunol (2005) 5(1):31–42. doi:10.1038/
nri1531 
 213. Bedel R, Matsuda JL, Brigl M, White J, Kappler J, Marrack P, et al. Lower 
TCR repertoire diversity in Traj18-deficient mice. Nat Immunol (2012) 
13(8):705–6. doi:10.1038/ni.2347 
 214. Heffernan DS, Monaghan SF, Thakkar RK, Tran ML, Chung CS, Gregory 
SH, et  al. Inflammatory mechanisms in sepsis: elevated invariant natural 
killer T-cell numbers in mouse and their modulatory effect on macrophage 
function. Shock (2013) 40(2):122–8. doi:10.1097/SHK.0b013e31829ca519 
 215. Koide N, Morikawa A, Odkhuu E, Haque A, Badamtseren B, Naiki Y, et al. Low 
susceptibility of NC/Nga mice to the lipopolysaccharide-mediated lethality 
with d-galactosamine sensitization and the involvement of fewer natural killer 
T cells. Innate Immun (2012) 18(1):35–43. doi:10.1177/1753425910390400 
 216. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensiti-
zation to the lethal effects of endotoxin. Proc Natl Acad Sci U S A (1979) 
76(11):5939–43. doi:10.1073/pnas.76.11.5939 
 217. Mannik LA, Chin-Yee I, Sharif S, Van Kaer L, Delovitch TL, Haeryfar SM. 
Engagement of glycosylphosphatidylinositol-anchored proteins results 
in enhanced mouse and human invariant natural killer T cell responses. 
Immunology (2011) 132(3):361–75. doi:10.1111/j.1365-2567.2010.03369.x 
 218. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, et al. Lethal endo-
toxic shock using alpha-galactosylceramide sensitization as a new experi-
mental model of septic shock. Lab Invest (2006) 86(3):254–61. doi:10.1038/
labinvest.3700388 
 219. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting 
edge: cross-talk between cells of the innate immune system: NKT cells rapidly 
activate NK cells. J Immunol (1999) 163(9):4647–50. 
 220. Tumurkhuu G, Koide N, Dagvadorj J, Morikawa A, Hassan F, Islam S, et al. 
The mechanism of development of acute lung injury in lethal endotoxic 
shock using alpha-galactosylceramide sensitization. Clin Exp Immunol 
(2008) 152(1):182–91. doi:10.1111/j.1365-2249.2008.03603.x 
 221. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, et al. 
Mechanisms of the antimetastatic effect in the liver and of the hepatocyte 
injury induced by alpha-galactosylceramide in mice. J Immunol (2001) 
166(11):6578–84. doi:10.4049/jimmunol.166.11.6578 
 222. Yokochi T. A new experimental murine model for lipopolysaccharide-me-
diated lethal shock with lung injury. Innate Immun (2012) 18(2):364–70. 
doi:10.1177/1753425911410236 
 223. Dieli F, Sireci G, Russo D, Taniguchi M, Ivanyi J, Fernandez C, et al. Resistance 
of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp 
Med (2000) 192(11):1645–52. doi:10.1084/jem.192.11.1645 
 224. Sireci G, La Manna MP, Di Liberto D, Lo Dico M, Taniguchi M, Dieli F, 
et al. Prophylaxis of lipopolysaccharide-induced shock by alpha-galactosyl-
ceramide. J Leukoc Biol (2008) 84(2):550–60. doi:10.1189/jlb.0707499 
August 2015 | Volume 6 | Article 40123
Szabo et al. NKT and MAIT cells in sepsis
Frontiers in Immunology | www.frontiersin.org
 225. Sireci G, La Manna MP, Di Sano C, Di Liberto D, Porcelli SA, Kronenberg M, 
et al. Pivotal advance: alpha-galactosylceramide induces protection against 
lipopolysaccharide-induced shock. J Leukoc Biol (2007) 81(3):607–22. 
doi:10.1189/jlb.0506298 
 226. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, 
et  al. Glycolipid antigen induces long-term natural killer T cell anergy in 
mice. J Clin Invest (2005) 115(9):2572–83. doi:10.1172/JCI24762 
 227. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity 
of disease classification system. Crit Care Med (1985) 13(10):818–29. 
doi:10.1097/00003246-198510000-00009 
 228. Ly D, Tohn R, Rubin B, Blumenfeld H, Besra GS, Veerapen N, et  al. An 
alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory 
and regulatory T cell-independent responses that prevent type 1 diabetes. Clin 
Exp Immunol (2010) 160(2):185–98. doi:10.1111/j.1365-2249.2009.04074.x 
 229. Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, et al. 
Stimulation of a shorter duration in the state of anergy by an invariant natural 
killer T cell agonist enhances its efficiency of protection from type 1 diabetes. 
Clin Exp Immunol (2011) 164(1):26–41. doi:10.1111/j.1365-2249.2011.04323.x 
 230. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, et  al. 
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants 
of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 102(9):3383–8. 
doi:10.1073/pnas.0407488102 
 231. Chau TA, McCully ML, Brintnell W, An G, Kasper KJ, Vines ED, et  al. 
Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate 
superantigen-induced T cell activation and prevent toxic shock syndrome. 
Nat Med (2009) 15(6):641–8. doi:10.1038/nm.1965 
 232. Higashi H, Suzuki Y, Mukaida N, Takahashi N, Miyamoto D, Matsushima 
K. Intervention in endotoxin shock by sulfatide (I3SO3-GalCer) with a con-
comitant reduction in tumor necrosis factor alpha production. Infect Immun 
(1997) 65(4):1223–7. 
 233. Squadrito F, Bagnato G, Altavilla D, Ferlito M, Campo GM, Squadrito G, 
et al. Effect of sulfatide on acute lung injury during endotoxemia in rats. Life 
Sci (1999) 65(24):2541–52. doi:10.1016/S0024-3205(99)00523-8 
 234. Kwiecinski J, Rhost S, Lofbom L, Blomqvist M, Mansson JE, Cardell SL, et al. 
Sulfatide attenuates experimental Staphylococcus aureus sepsis through a 
CD1d-dependent pathway. Infect Immun (2013) 81(4):1114–20. doi:10.1128/
IAI.01334-12 
 235. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated 
anergy induction in type I NKT cells prevents inflammatory liver disease. J 
Clin Invest (2007) 117(8):2302–12. doi:10.1172/JCI31602 
 236. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II 
natural killer T cells prevents hepatic ischemic reperfusion injury in mice. 
Gastroenterology (2011) 140(2):646–55. doi:10.1053/j.gastro.2010.10.003 
 237. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz 
F, et  al. Specific MAIT cell behaviour among innate-like T lymphocytes 
in critically ill patients with severe infections. Intensive Care Med (2014) 
40(2):192–201. doi:10.1007/s00134-013-3163-x 
 238. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, et  al. 
Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 
(2010) 11(8):701–8. doi:10.1038/ni.1890 
 239. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. 
Human mucosal associated invariant T cells detect bacterially infected cells. 
PLoS Biol (2010) 8(6):e1000407. doi:10.1371/journal.pbio.1000407 
 240. Morison R. Remarks on some functions of the omentum. Br Med J (1906) 
1(2350):76–8. doi:10.1136/bmj.1.2350.76 
 241. van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Esposti MA. Activation of 
natural killer (NK) T cells during murine cytomegalovirus infection enhances 
the antiviral response mediated by NK cells. J Virol (2003) 77(3):1877–84. 
doi:10.1128/JVI.77.3.1877-1884.2003 
 242. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, et  al. The 
majority of CD1d-sulfatide-specific T cells in human blood use a semi 
invariant Vdelta1 TCR. Eur J Immunol (2012) 42(9):2505–10. doi:10.1002/
eji.201242531 
 243. Luoma AM, Castro CD, Mayassi T, Bembinster LA, Bai L, Picard D, et al. 
Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfatide 
shows MHC-like recognition of a self-lipid by human gammadelta T cells. 
Immunity (2013) 39(6):1032–42. doi:10.1016/j.immuni.2013.11.001 
 244. Maricic I, Girardi E, Zajonc DM, Kumar V. Recognition of lysophosphati-
dylcholine by type II NKT cells and protection from an inflammatory liver 
disease. J Immunol (2014) 193(9):4580–9. doi:10.4049/jimmunol.1400699 
 245. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, et  al. 
Cross-regulation between type I and type II NKT cells in regulating tumor 
immunity: a new immunoregulatory axis. J Immunol (2007) 179(8):5126–36. 
doi:10.4049/jimmunol.179.8.5126 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Szabo, Anantha, Shaler, McCormick and Haeryfar. This is 
an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
